

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## USE OF 18F-NaF-PET IN THE STAGING OF SKELETAL METASTASES OF NEWLY DIAGNOSED, HIGH-RISK PROSTATE CANCER PATIENTS - A NATIONWIDE COHORT STUDY.

|                               |  |
|-------------------------------|--|
| Journal:                      | <i>BMJ Open</i>  |
| Manuscript ID                 | bmjopen-2021-058898  |
| Article Type:                 | Original research  |
| Date Submitted by the Author: | 08-Nov-2021  |
| Complete List of Authors:     | Mogensen, Anna Winther; Aalborg University Hospital, Department of Nuclear Medicine<br>Petersen, Lars J; Aalborg University Hospital, Department of Nuclear Medicine; Aalborg University, Department of Clinical Medicine<br>Torp-Pedersen, Christian; Nordsjællands Hospital<br>Nørgaard, Mette; Aarhus University Hospital, Department of Clinical Epidemiology<br>Pank, Marie T; Aalborg University Hospital, Department of Urology<br>Zacho, Helle; Aalborg University Hospital, Department of Nuclear Medicine; Aalborg University, Department of Clinical Medicine |
| Keywords:                     | NUCLEAR MEDICINE, ONCOLOGY, Epidemiology < ONCOLOGY, Urological tumours < UROLOGY  |
|                               |  |

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# TITLE PAGE

## USE OF $^{18}\text{F}$ -NaF-PET IN THE STAGING OF SKELETAL METASTASES OF NEWLY DIAGNOSED, HIGH-RISK PROSTATE CANCER PATIENTS - A NATIONWIDE COHORT STUDY.

### Corresponding author

PhD student, Anna W Mogensen, MSc  
Department of Nuclear Medicine  
Aalborg University Hospital  
Hobrovej 18-22, 9000 Aalborg, Denmark  
E-mail: [anna.w@rn.dk](mailto:anna.w@rn.dk)  
Tlf. +45 2876 6353

### Co-Authors

Professor Emeritus, Lars J Petersen, MD, DMSc  
Department of Nuclear Medicine  
Aalborg University Hospital, Denmark  
[jp@dadlnet.dk](mailto:jp@dadlnet.dk)

Professor, Christian Torp-Pedersen, MD, DMSc  
Department of Clinical Investigations and Department of Cardiology  
Nordsjaellands Hospital, Denmark  
[christian.torp-pedersen.01@regionh.dk](mailto:christian.torp-pedersen.01@regionh.dk)

Professor, Mette Nørgaard, MD, PhD  
Department of Clinical Epidemiology  
Aarhus University Hospital, Denmark  
[mn@clin.au.dk](mailto:mn@clin.au.dk)

Chief Physician, Marie T Pank, MD  
Department of Urology  
Aalborg University Hospital, Denmark  
[mtp@rn.dk](mailto:mtp@rn.dk)

Associate Professor, Helle D Zacho, MD, PhD  
Department of Nuclear Medicine  
Aalborg University Hospital, Denmark  
[h.zacho@rn.dk](mailto:h.zacho@rn.dk)

**Word count (introduction, methods, results, discussion): 3066**

1  
2  
3  
4 **USE OF <sup>18</sup>F-NaF-PET IN THE STAGING OF SKELETAL METASTASES OF NEWLY**  
5 **DIAGNOSED, HIGH-RISK PROSTATE CANCER PATIENTS - A NATIONWIDE COHORT**  
6 **STUDY.**  
7  
8  
9

10 Anna W Mogensen<sup>1</sup>, Lars J Petersen<sup>1,2</sup>, Christian Torp-Pedersen<sup>3</sup>, Mette Nørgaard<sup>4</sup>, Marie T Pank<sup>5</sup>, Helle D  
11 Zacho<sup>1,2</sup>  
12

13 <sup>1</sup>Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University  
14 Hospital, Aalborg, Denmark, <sup>2</sup>Department of Clinical Medicine, Aalborg University, Aalborg  
15 Denmark, <sup>3</sup>Department of Clinical Investigations and Department of Cardiology, Nordsjaellands Hospital,  
16 Denmark, <sup>4</sup>Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark,  
17 <sup>5</sup>Department of Urology, Aalborg University Hospital, Aalborg, Denmark.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 **Corresponding author**

45 Anna W Mogensen

46 Dept. of Nuclear Medicine

47 Aalborg University Hospital

48 Hobrovej 18-22, Postboks 365

49 DK-9100 Aalborg, Denmark

50 Tel: +45 2876 6353

51 E-mail: [anna.w@rn.dk](mailto:anna.w@rn.dk)  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective** To determine whether preoperative staging of high-risk prostate cancer with  $^{18}\text{F}$ -NaF PET reduces the risk of skeletal metastases.

**Design** Nationwide, population-based cohort study using real-world data.

**Setting** The study used national health registries, including all sites in Denmark from 2011-2018.

**Participants** Newly diagnosed high-risk prostate cancer patients who underwent radical prostatectomy from 2011-2018. Patients were stratified into two groups according to the preoperative imaging modality of either  $^{18}\text{F}$ -NaF PET or bone scintigraphy.

**Main outcome measures** The risk of skeletal-related events as a proxy for skeletal metastases following radical prostatectomy. The secondary endpoint was overall survival.

**Results** Between January 1, 2011, and December 31, 2018, 4,183 high-risk patients underwent radical prostatectomy. Of these patients, 807 (19.3%) underwent  $^{18}\text{F}$ -NaF PET and 2,161 (51.7%) underwent bone scintigraphy. The remaining 30% were examined by a different imaging method or did not undergo imaging. Using the inverse probability of treatment weighting to control potential confounding, the hazard ratio of experiencing a skeletal-related event for patients in the  $^{18}\text{F}$ -NaF PET group versus the bone scintigraphy group was 1.15 (95% CI 0.86-1.54). The 3-year survival rates were 97.4% (95% CI 96.1-98.7) and 97.1% (95% CI 96.4-97.9) for patients receiving  $^{18}\text{F}$ -NaF PET and bone scintigraphy, respectively.

**Conclusion** High-risk prostate cancer patients undergoing preoperative staging with  $^{18}\text{F}$ -NaF PET did not display a lower risk of developing skeletal-related events after prostatectomy compared to patients undergoing bone scintigraphy. The survival rates were similar between the two groups. The results of this study support the existing guidelines that recommend bone scintigraphy as the first choice in the primary staging of prostate cancer.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

#### **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- This study identified a cohort from all institutions in Denmark using high-quality registry data.
- The study uses routinely collected health data that is not specifically collected for the purposes of this research, resulting in a minor degree of missing data.
- Regression analysis weighted by the inverse probability of treatment ensured consideration of all measured confounders and addressed confounding by indication.
- This large cohort study using real-world data provides the first evidence that there is no clinical benefit of <sup>18</sup>F-NaF PET in terms of patient-relevant outcomes.

For peer review only

## INTRODUCTION

Prostate cancer is one of the most common malignancies in the Western world, with over 1.4 million new cases reported in 2020.<sup>1</sup> Prostate cancer frequently metastasizes to the bone, which is associated with significant morbidity and mortality.<sup>2,3</sup> Accurate detection of bone metastases at primary staging is essential for decision-making regarding subsequent management. At the time of diagnosis, the risk of recurrence is determined based on the PSA level, Gleason score, and clinical tumour stage (T-stage).<sup>4</sup> Patients classified as unfavorable–intermediate risk or high risk will often receive preoperative staging by imaging. International urology and oncology guidelines recommend bone scintigraphy with 99mTechnetium-labeled phosphonate (99mTc) for the assessment of bone metastases at primary staging.<sup>4,5</sup>

However, several studies have shown that the bone-specific positron emission tomography (PET) tracer <sup>18</sup>F-sodium-fluoride (<sup>18</sup>F-NaF) is superior to bone scintigraphy in terms of its diagnostic accuracy for detecting bone metastases including fewer equivocal findings.<sup>6-8</sup> In previous studies, the sensitivity of bone scintigraphy for the detection of bone metastases varied from 57% to 97%, and the specificity varied from 57 to 80%.<sup>6-9</sup> In contrast, the sensitivity of <sup>18</sup>F-NaF PET for the diagnosis of bone metastases has ranged from 81 to 100% in the majority of studies, with a specificity ranging from 71 to 100%.<sup>6-8,10,11</sup> With the purported lower accuracy of bone scintigraphy, the risk of misdiagnosing patients is high, possibly resulting in suboptimal treatment strategies. Among patients referred for suspected metastases, the use of <sup>18</sup>F-NaF PET instead of bone scintigraphy in patients with prostate cancer has been shown to affect the patient management strategy in 6-12% of cases.<sup>12,13</sup> However, no studies have documented that the subsequent change in patient management strategies induced by <sup>18</sup>F-NaF PET and its improved diagnostic accuracy confer any patient benefit in terms of mortality, morbidity and quality of life. Thus, we performed a cohort study with real-world data of men diagnosed with prostate cancer in Denmark who underwent either bone scintigraphy or <sup>18</sup>F-NaF PET as part of primary staging before curative intent prostatectomy to examine whether the type of preoperative imaging modality was associated with overall survival and skeletal-related events (SREs) after radical prostatectomy.



## METHODS

### Study Population and Data Sources

This nationwide register-based cohort study was conducted in Denmark, which has approximately 5.8 million residents. In Denmark, all residents are provided with free, tax-supported health care by the National Health Service. A unique 10-digit civil registration number is assigned to all residents at birth by the Central Office of Civil Registration. This number allows unambiguous linkage across all Danish population-based registries.<sup>14</sup> Reporting to the registries by clinicians is mandatory, which ensures high completeness of medical information. The applied data included nationwide information from the Danish Cancer Registry,<sup>15</sup> the Civil Registration System,<sup>16</sup> the Danish National Patient Registry,<sup>17</sup> the Register of Laboratory Results for Research,<sup>18</sup> the Danish Prostate Cancer Database,<sup>19</sup> the Danish National Pathology Register,<sup>20</sup> and the Register of Causes of Death.<sup>21</sup> Appendix 1 (p 1) provides a detailed description of the codes found in the registries for prostate cancer characteristics, treatment, outcomes, and covariates. Furthermore, the study is reported in accordance with STROBE guidelines, and a checklist is provided in the supplementary files.

### Identifying Men with Prostate Cancer

No formal screening program for prostate cancer existed during the study period. Therefore, men were referred to the urology department upon suspicion of prostate cancer. We used the Danish National Patient Registry to identify a cohort consisting of men with a first-time prostate cancer diagnosis from 2011 through 2018 who had undergone radical prostatectomy. This registry was established in 1977 for hospitalized patients; outpatient visits at hospitals have been included since 1995.<sup>17</sup> The registry includes dates of admission and discharge, diagnosis (ICD-10 codes), surgical procedures, and treatment information. The validity of a prostate cancer diagnosis in this register has previously been evaluated and found to be high, with a positive predictive value of nearly 90%.<sup>22</sup>

### Risk Classification

We restricted the cohort to patients we could classify as having a preoperative high risk of cancer recurrence according to the European Association of Urology (EAU) risk classification of prostate cancer. The EAU defines high-risk patients as those with a PSA of more than 20 ng/mL OR a Gleason score >7 OR a T-stage of T2c as the minimum.<sup>4</sup> PSA values were retrieved from the Danish Register of Laboratory Results, which includes laboratory data from four of the five regions of Denmark.<sup>18</sup> Data from the last region were obtained directly from the relevant regional database. The Gleason score was obtained from the Pathology Register, which contains information on all pathological examinations conducted in Denmark since 1997. T-stage was obtained from the Danish Cancer Registry, which has prospectively recorded all cancers diagnosed in Denmark since 1943, classified according to ICD-10, and ICD Oncology codes (ICD-O-3) for topography and morphology.<sup>15</sup> For all three variables, we included the latest recorded value within six months prior to surgery. If PSA, Gleason score, or T-stage were missing, we used the Danish Prostate Cancer Database to fill in the

1  
2  
3  
4 missing variables. This register is a nationwide clinical cancer database established in 2010 that records data  
5 on all incident, historically verified prostate cancer cases.  
6  
7

### 8 **Imaging Modality**

9 We retrieved information on imaging modalities from the Danish National Patient Registry. We identified the  
10 preoperative use of bone scintigraphy and  $^{18}\text{F}$ -NaF PET, recorded up to 6 months before surgery, combined  
11 with computer tomography (CT) or magnetic resonance imaging (MRI). Single-photon emission (SPECT)/CT  
12 was conducted according to institutional practices. Patients were categorized according to their preoperative  
13 imaging into two groups: those who underwent bone scintigraphy only (bone scintigraphy group) and those  
14 who underwent  $^{18}\text{F}$ -NaF PET scan with or without bone scintigraphy ( $^{18}\text{F}$ -NaF PET group). In general, each  
15 site performed only one of the two scans; thus, physicians did not stratify patients according to a specific  
16 imaging modality. Patients with an  $^{18}\text{F}$ -NaF PET scan performed as a part of a clinical research project were  
17 excluded from the cohort because the results of these scans were not made available to the referring physician.  
18  
19  
20  
21  
22  
23

### 24 **SREs and Bone Metastases**

25 We obtained information on SREs through the Danish National Patient Registry. SREs comprised the  
26 following events occurring after the date of radical prostatectomy: radiation to the bone defined as 1-4  
27 treatments with external radiation therapy (standard practice in Denmark), pathological and osteoporotic  
28 fractures, spinal cord compression, surgery to the bone, or a first-time bone metastasis diagnosis code.  
29  
30  
31  
32

### 33 **Mortality**

34 Mortality and migration updates were obtained from the Civil Registration System, which is updated daily.<sup>14</sup>  
35 The register contains information on the vital status (dead or alive), date of death, and migration status of all  
36 Danish citizens.  
37  
38  
39

### 40 **Comorbidity**

41 We used the Charlson comorbidity index to describe preexisting comorbidities in the prostate cancer cohort<sup>23</sup>  
42 (appendix 1 p 2). We calculated the index based on diagnoses recorded in the Danish National Patient Registry  
43 up to ten years before the date of surgery. For analysis, we categorized the index into 3 comorbidity levels,  
44 including 1) those without comorbidity, 2) those with a comorbidity index equal to 1, and 3) those with a  
45 comorbidity index above 1.  
46  
47  
48  
49

### 50 **Statistical Analysis**

51 Baseline characteristics are reported as frequencies with percentages and medians with interquartile ranges.  
52 We estimated the cumulative risk of SREs according to the type of imaging modality and plotted the  
53 cumulative risk as a function of time since radical prostatectomy; death was treated as a competing risk event.  
54 Patients contributed time at risk from the date of radical prostatectomy until the date of first-time registered  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

SRE, migration, death, or December 31, 2018, whichever came first. Finally, we similarly estimated the cumulative incidence of death.

For the main analysis, we used Cox proportional hazards regression analysis to estimate the age-adjusted and multivariate-adjusted hazard ratios (HRs) of SREs with 95% CIs, comparing those who underwent  $^{18}\text{F}$ -NaF PET scans with those who underwent bone scintigraphy. Additionally, to better control potential confounding by indication, analysis of the inverse probability of treatment weighting (IPTW) was performed based on the propensity score for  $^{18}\text{F}$ -NaF PET. Propensity scores were calculated using logistic regression with the inclusion of the same variables as in the adjusted Cox analysis. We adjusted for age, Charlson comorbidity index, PSA (categorical variable: <10, 10-20, >20 ng/mL), Gleason score (categorical variable: <7, 7, >7), and T-stage (categorical variable: T1, T2, T3+T4). Adjusting with categorical variables was deemed necessary due to outliers and the limited number of records available on the outer areas of the scales. Furthermore, we stratified the analysis by PSA, Gleason score, T-stage, and year of radical prostatectomy. In the stratified analysis, we only adjusted for age and Charlson comorbidity index. An adjusted HR of death was also calculated. No further analyses were performed for patients with other types of imaging or no imaging before surgery.

Several sensitivity analyses were performed to test the robustness of our findings, including an analysis restricted to the capitol region of Denmark and the reclassification of the exposure group to include patients with both scans. An additional regression analysis was performed with imputed data on the missing values of PSA, Gleason score, and T-stage using multiple imputations.<sup>24</sup>

### **Statistical software**

Data management and analyses were conducted in R 4.0.3 using RStudio 2020 (RStudio, PBC, Boston, MA) with the following packages: heaven, data.table, Publish, survival, stringr, mitools, smcfcs and ipw.

### **Ethics Approval**

The Danish Data Protection Agency approved the use of data for this study (reference number 2008-58-0028). Furthermore, the study was granted approval by the Danish Patient Safety Authority to collect laboratory data (reference numbers 3-3013-3183/1 and 31-1522-37). Ethics approval is not required for historical register-based studies in Denmark.

### **Patient and public involvement**

This study was observational and based on data from routine healthcare records. No patients were directly involved in the study.

## RESULTS

Between January 1, 2011, and December 31, 2018, 36,910 men were diagnosed with prostate cancer in Denmark, of whom 8,726 (23.6%) underwent radical prostatectomy (Figure 1). Among those who underwent radical prostatectomy, 4,183 patients (47.9%) were classified as high risk according to the EAU preoperative staging criteria. A total of 2,161 (51.7%) high-risk patients undergoing surgery were evaluated for skeletal metastasis with bone scintigraphy only, and 807 (19.3%) men were evaluated with  $^{18}\text{F}$ -NaF PET. Information on the PSA values, Gleason score, and T-stage from the registries ensured nearly 90% completeness of the high-risk classification, resulting in a large study population for our analysis. A notable proportion of high-risk patients (28.5%) underwent different imaging modalities or no imaging to evaluate bone metastasis, and a small portion of patients (0.5%) were excluded because they underwent project-related imaging. The median age at the date of radical prostatectomy was 67 years (interquartile range, 62-70.1), and the median follow-up from surgery was 4.1 years (interquartile range, 2.4-6.0 years). In general, patients receiving  $^{18}\text{F}$ -NaF PET had a higher PSA level, Gleason score, and T-stage at primary staging (Table 1).

### SREs and Bone Metastases

The unadjusted one-year cumulative risk of SREs was 2.4% (95% CI 1.8-3.1) for men who underwent bone scintigraphy and 4.3% (95% CI 2.8-5.7) for those who underwent  $^{18}\text{F}$ -NaF PET (Figure 2). The unadjusted 3-year cumulative risk of SREs was 7.2% (95% CI 6.0-8.3) for men undergoing bone scintigraphy and 11.9% (95% CI 9.4-14.4) for those undergoing  $^{18}\text{F}$ -NaF PET. Of the 300 men with at least one SRE recorded during follow-up, 53.7% had radiation to bone recorded as their first event, 30.7% had a pathological or osteoporotic fracture, 6.3% had spinal cord compression, 6.3% had a code for bone metastases, and 3.0% had bone surgery. In the main analysis, we did not find that  $^{18}\text{F}$ -NaF PET decreased the HR of experiencing SREs after surgery; in contrast, we observed a slightly increased HR, which was reduced when adjusting the model (adjusted HR, 1.22; 95% CI 0.93-1.61; Figure 3). When we used IPTW to control for potential confounding factors, the risk of experiencing an SRE was attenuated (IPTW adjusted HR, 1.15; 95% CI 0.86-1.54; Figure 3). Stratified analyses similarly demonstrated increased HRs for SREs in patients undergoing  $^{18}\text{F}$ -NaF PET compared to those undergoing bone scintigraphy, except for patients with stage 2 disease and those with a Gleason score <7 (Figure 3).

### Survival

Figure 4 shows the cumulative survival curves of the cohorts for up to 7 years of follow-up. The one-year survival was 99.4% (95% CI 99.0-99.7) in men who underwent bone scintigraphy and 99.5% (95% CI 98.9-100) in men who underwent  $^{18}\text{F}$ -NaF PET, and the corresponding 3-year survival rates in the cohorts were 97.1% (95% CI 96.4-97.9) and 97.4% (95% CI 96.1-98.7), respectively. Adjusted analyses showed a modest reduction in mortality for patients who underwent  $^{18}\text{F}$ -NaF PET (adjusted HR, 0.89; 95% CI 0.61-1.30).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Sensitivity Analysis**

Restricting to patients from the capitol region yielded cumulative SRE risk estimates consistent with those of the main analysis (appendix 1 p 3). Similar to the main analysis, the cumulative risk of SREs was higher for men evaluated with  $^{18}\text{F}$ -NaF PET than for those evaluated with bone scintigraphy. Adjusted analysis for the capitol region was also comparable to the main analysis (appendix 1 p 4) and did not suggest any added value of using  $^{18}\text{F}$ -NaF PET.

Including patients with both bone scintigraphy and  $^{18}\text{F}$ -NaF PET in the bone scintigraphy group or excluding them entirely yielded HRs similar to those of the main analysis. A final analysis with imputed values for PSA, Gleason score, and T-stage yielded HRs similar to those of the analysis without imputation.

## DISCUSSION

### Principal findings

In this nationwide cohort study of Danish patients with high-risk prostate cancer undergoing prostatectomy, we found that preoperative staging with  $^{18}\text{F}$ -NaF PET did not reduce the risk of SREs compared to staging with bone scintigraphy, whereas a slight tendency towards a reduction in all-cause mortality was observed in the group undergoing  $^{18}\text{F}$ -NaF PET. To the best of our knowledge, this is the first study to evaluate patient-relevant outcomes of using a PET-based method for primary staging.

### Comparison with other studies

Prior studies on  $^{18}\text{F}$ -NaF PET in prostate cancer have focused on its improvements in diagnostic accuracy compared to bone scintigraphy<sup>6-8</sup> or its impact on patient management.<sup>12 13</sup> The superior diagnostic performance of  $^{18}\text{F}$ -NaF PET should presumably result in improved patient selection for curative and life-prolonging treatment, leading to improvements in patient-relevant outcomes. However, in this study, we did not observe any superiority over bone scintigraphy in terms of patient benefit among newly diagnosed, high-risk prostate cancer patients.

Evidence of patient-relevant outcomes is often reported from randomized controlled trials. Randomized trials are, however, not commonly conducted within the field of imaging, and it has previously been debated whether randomized trials are necessary to evaluate diagnostic procedures. In prostate cancer, only two randomized controlled trials have been published, employing PET in one arm and standard imaging in the other arm. One such trial confirmed the diagnostic superiority of PSMA PET/CT during primary staging<sup>25</sup>, whereas the other trial focused on the changes in patient management based on fluciclovine PET/CT at the time of biochemical recurrence;<sup>26</sup> none of these trials were linked to patient-relevant outcomes.

Randomized trials have demonstrated the clinical benefit of PET within other types of cancers, such as haematological and lung cancers.<sup>27</sup> Fischer et al. compared preoperative staging with FDG PET/CT to conventional staging by CT in lung cancer patients and found that patients in the PET/CT group showed a reduction in both the total number of thoracotomies and the number of futile thoracotomies; however, they did not observe a decrease in overall mortality.<sup>28</sup> Similar results were reported for colorectal liver metastases, with one study finding that FDG PET led to a reduction in futile laparotomies in 1 of 6 patients.<sup>29</sup> It could be expected that the use of  $^{18}\text{F}$ -NaF PET would reduce the number of “futile” prostatectomies in patients harboring bone metastases at the time of diagnosis, thereby reducing the incidence of SREs postoperatively. With recent trials demonstrating superior diagnostic properties of PSMA PET for primary staging in high-risk prostate cancer, its impact on treatment choice—and perhaps outcome—is likely to be greater than that of  $^{18}\text{F}$ -NaF PET.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations

The major strengths of our study are its national scale, large cohort, high-quality registry data, and complete follow-up. The registration of information related to prostate cancer diagnosis and radical prostatectomy, as well as variables defining the high-risk population, is thought to be practically complete because of a uniformly organized health care system where healthcare is free (tax-supported) and available to all residents.<sup>30</sup> Furthermore, a median follow-up time of 4.1 years is adequate for the purpose of evaluating bone metastases not captured by the imaging modality at primary staging; hence, only patients with a negative scan will undergo radical prostatectomy with curative intent in Denmark.

Nevertheless, our study has several limitations worth considering. The potential of confounding by indication was particularly concerning because of the observed higher values for PSA, Gleason score, and T-stage in the <sup>18</sup>F-NaF PET group; however, the indication of usage was the same for both scans. Moreover, the demographics of the groups might have been more alike if the International Society of Urological Pathology (ISUP) grading system was used for the Gleason score, which distinguishes between normal high-risk prostate cancer and very high-risk (ISUP grade 5) cancer cases. It was not possible to use the ISUP grading due to unavailability in some of the registers. Furthermore, confounding by indication is only an issue in hospitals that offer both bone scintigraphy and <sup>18</sup>F-NaF PET, which is highly uncommon in Denmark. Since sites only used one of the imaging modalities, physicians did not have to choose between the two, resulting in minimal selection bias. We attempted to control for confounding by using a propensity score-based inverse probability of treatment weighting, but we cannot rule out residual confounding due to misclassified or unmeasured prognostic factors.

In the present study, we defined SREs as either external radiation therapy, pathological or osteoporotic fractures, spinal cord compression, surgery to the bone, or a bone metastases code. It can be speculated that patients treated at a site using <sup>18</sup>F-NaF PET would undergo <sup>18</sup>F-NaF PET rather than bone scintigraphy in case of biochemical recurrence, thereby increasing the detection of bone metastases during follow-up. However, the risk of SREs was primarily driven by a high percentage of radiotherapy of bone or fracture cases, which are not related to <sup>18</sup>F-NaF PET. Information regarding bone metastases was noted in only 6.3% of SREs across the groups.

### Conclusions

In conclusion, we found that the use of <sup>18</sup>F-NaF PET at primary staging did not improve patient-relevant outcomes in terms of a reduction in SREs compared to that with bone scintigraphy.

## ACKNOWLEDGMENT SECTION

### Author Contributions

AWM, LJP and HDZ conceived the study and contributed to the literature search. AWM and CTP had access to the data and carried out the data management and analysis. AWM, CTP and MN designed the graphs. AWM, LJP, HDZ, CTP, MN and MTP aided in the interpretation of results. AWM prepared the first draft of the paper. All authors contributed to critical revision and approval of the final draft of the paper.

### Conflict of Interest Disclosure

All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: one author received grants from Bayer and Novo Nordisk for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

### Data availability statement

Data is not available to other researchers due to Registry or institutional database of patients providing routinely collected data.

### Funding/Support

Funding was received from the North Denmark Region's Fund for Health Sciences Research and from Knud and Edith Eriksens Mindefond. Award numbers are not applicable.

### Role of Funder/Sponsor

The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60**REFERENCES**

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians* 2021 doi: 10.3322/caac.21660 [published Online First: 2021/02/05]
2. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. *Nat Rev Cancer* 2005;5(1):21-8. doi: 10.1038/nrc1528 [published Online First: 2005/01/05]
3. Nørgaard M, Jensen A, Jacobsen JB, et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). *The Journal of urology* 2010;184(1):162-7. doi: 10.1016/j.juro.2010.03.034 [published Online First: 2010/05/21]
4. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *European urology* 2020 doi: 10.1016/j.eururo.2020.09.042 [published Online First: 2020/11/12]
5. NCCN. Clinical practice guidelines in oncology, Prostate Cancer version 2.2020, May 21 2020 [Available from: <http://www.nccn.com>]
6. Jambor I, Kuisma A, Ramadan S, et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. *Acta oncologica (Stockholm, Sweden)* 2016;55(1):59-67. doi: 10.3109/0284186x.2015.1027411 [published Online First: 2015/04/03]
7. Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine* 2006;47(2):287-97. [published Online First: 2006/02/04]
8. Igaru A, Mittra E, Dick DW, et al. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. *Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging* 2012;14(2):252-9. doi: 10.1007/s11307-011-0486-2 [published Online First: 2011/04/12]
9. Palmedo H, Marx C, Ebert A, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. *European journal of nuclear medicine and molecular imaging* 2014;41(1):59-67. doi: 10.1007/s00259-013-2532-6 [published Online First: 2013/08/27]
10. Langsteger W, Balogova S, Huchet V, et al. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by

- 1  
2  
3  
4 masked reading. *The quarterly journal of nuclear medicine and molecular imaging : official*  
5 *publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International*  
6 *Association of Radiopharmacology (IAR), [and] Section of the So* 2011;55(4):448-57. [published  
7  
8 Online First: 2011/07/09]
- 9  
10
- 11 11. Mosavi F, Johansson S, Sandberg DT, et al. Whole-body diffusion-weighted MRI compared with (18)F-  
12 NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. *AJR*  
13 *American journal of roentgenology* 2012;199(5):1114-20. doi: 10.2214/ajr.11.8351 [published  
14  
15 Online First: 2012/10/26]
- 16  
17
- 18 12. Gauthé M, Aveline C, Lecouvet F, et al. Impact of sodium (18)F-fluoride PET/CT, (18)F-fluorocholine  
19 PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate  
20 cancer suspicious for metastasis: a prospective multicentre study. *World journal of urology*  
21 2019;37(8):1587-95. doi: 10.1007/s00345-018-2547-5 [published Online First: 2018/11/02]
- 22  
23
- 24 13. Hillner BE, Hanna L, Makinen R, et al. Intended Versus Inferred Treatment After (18)F-Fluoride PET  
25 Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry.  
26 *Journal of nuclear medicine : official publication, Society of Nuclear Medicine* 2018;59(3):421-26.  
27 doi: 10.2967/jnumed.117.205047 [published Online First: 2017/12/02]
- 28  
29
- 30 14. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. *Eur*  
31 *J Epidemiol* 2014;29(8):541-9. doi: 10.1007/s10654-014-9930-3 [published Online First:  
32  
33 2014/06/27]
- 34  
35
- 36 15. Gjerstorff ML. The Danish Cancer Registry. *Scand J Public Health* 2011;39(7 Suppl):42-5. doi:  
37  
38 10.1177/1403494810393562 [published Online First: 2011/08/04]
- 39  
40
- 41 16. Pedersen CB. The Danish Civil Registration System. *Scand J Public Health* 2011;39(7 Suppl):22-5. doi:  
42  
43 10.1177/1403494810387965 [published Online First: 2011/08/04]
- 44  
45
- 46 17. Schmidt M, Schmidt SA, Sandegaard JL, et al. The Danish National Patient Registry: a review of content,  
47 data quality, and research potential. *Clin Epidemiol* 2015;7:449-90. doi: 10.2147/clep.S91125  
48 [published Online First: 2015/11/26]
- 49  
50
- 51 18. Arendt JFH, Hansen AT, Ladefoged SA, et al. Existing Data Sources in Clinical Epidemiology: Laboratory  
52 Information System Databases in Denmark. *Clin Epidemiol* 2020;12:469-75. doi:  
53  
54 10.2147/clep.S245060 [published Online First: 2020/06/18]
- 55  
56
- 57 19. Nguyen-Nielsen M, Høyer S, Friis S, et al. The Danish Prostate Cancer Database. *Clin Epidemiol*  
58 2016;8:649-53. doi: 10.2147/clep.S100256 [published Online First: 2016/11/16]
- 59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

20. Erichsen R, Lash TL, Hamilton-Dutoit SJ, et al. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. *Clin Epidemiol* 2010;2:51-6. doi: 10.2147/clep.s9908 [published Online First: 2010/09/25]
21. Helweg-Larsen K. The Danish Register of Causes of Death. *Scand J Public Health* 2011;39(7 Suppl):26-9. doi: 10.1177/1403494811399958 [published Online First: 2011/08/04]
22. Gammelager HC, C.; Johansen, M.; Borre, M.; Schoonen, M.; Sørensen, H. Quality of urological cancer diagnoses in the Danish National Registry of Patients. *European Journal of Cancer Prevention* 2012;21(6):545-51. doi: 10.1097/CEJ.0b013e328351c680
23. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8 [published Online First: 1987/01/01]
24. Keogh JBaR. smcfcs: Multiple Imputation of Covariates by Substantive Model Compatible Fully Conditional Specification. . <http://www.missingdata.org.uk>, <http://thestatsgeek.com>. , 2020:17.
25. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. *Lancet* 2020;395(10231):1208-16. doi: 10.1016/s0140-6736(20)30314-7 [published Online First: 2020/03/27]
26. Akin-Akintayo OO, Jani AB, Odewole O, et al. Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer. *Clinical nuclear medicine* 2017;42(1):e22-e28. doi: 10.1097/rlu.0000000000001379 [published Online First: 2016/10/18]
27. Scheibler F, Zumbé P, Janssen I, et al. Randomized controlled trials on PET: a systematic review of topics, design, and quality. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine* 2012;53(7):1016-25. doi: 10.2967/jnumed.111.101089 [published Online First: 2012/06/09]
28. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. *N Engl J Med* 2009;361(1):32-9. doi: 10.1056/NEJMoa0900043 [published Online First: 2009/07/03]
29. Ruers TJ, Wiering B, van der Sijp JR, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine* 2009;50(7):1036-41. doi: 10.2967/jnumed.109.063040 [published Online First: 2009/06/16]

- 1  
2  
3  
4 30. Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research:  
5 from health care contacts to database records. *Clin Epidemiol* 2019;11:563-91. doi:  
6 10.2147/clep.S179083 [published Online First: 2019/08/03]  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## FIGURE LEGENDS

(Figure 1-4 are attached as separate PDF files)

### Figure 1: Study profile

Study cohort of 2,161 men undergoing presurgical imaging with bone scintigraphy and 807 men undergoing  $^{18}\text{F}$ -NaF PET.

### Figure 2: Unadjusted cumulative incidence of skeletal-related events (SREs)

The unadjusted cumulative incidence with 95% confidence intervals of SREs in men after undergoing radical prostatectomy. Death was treated as a competing event. The red curve represents  $^{18}\text{F}$ -NaF PET, and the black curve represents bone scintigraphy.

### Figure 3: Main analysis results

Hazard ratios for SREs following radical prostatectomy among patients undergoing  $^{18}\text{F}$ -NaF PET before surgery versus patients undergoing bone scintigraphy.

### Figure 4: Unadjusted cumulative incidence of death

Unadjusted cumulative incidence of death with 95% confidence intervals for men with prostate cancer after undergoing radical prostatectomy, stratified by type of imaging modality. The red curve represents  $^{18}\text{F}$ -NaF PET, and the black curve represents bone scintigraphy.

### Table 1: Baseline patient characteristics by imaging modality

Characteristics on the day of surgery for men with high-risk prostate cancer from 2011 to 2018. Percentages may not add up to 100 due to rounding or missing data. \*Top 3 comorbidities. Abbreviations: IQR, interquartile range; PSA, prostate specific antigen; T-stage, tumour stage.

## TABLES


**Table 1. Baseline patient characteristics by imaging modality**

|                            | Bone scintigraphy (n = 2,161) | <sup>18</sup> F-NaF PET (n = 807) | All (n = 2,968)   |
|----------------------------|-------------------------------|-----------------------------------|-------------------|
| Age (years, median (IQR))  | 66.3 (61.7, 69.7)             | 67.9 (62.9, 71.2)                 | 66.7 (62.0, 70.1) |
| Year of surgery            |                               |                                   |                   |
| 2011-2013                  | 852 (39.4)                    | 212 (26.3)                        | 1,064 (35.8)      |
| 2014-2015                  | 602 (27.9)                    | 235 (29.1)                        | 837 (28.2)        |
| 2016-2018                  | 707 (32.7)                    | 360 (44.6)                        | 1,067 (36.0)      |
| PSA (ng/mL)                |                               |                                   |                   |
| <10                        | 955 (45.0)                    | 263 (33.1)                        | 1,218 (41.8)      |
| 10-20                      | 642 (30.2)                    | 292 (36.8)                        | 934 (32.0)        |
| >20                        | 526 (24.8)                    | 239 (30.1)                        | 765 (26.2)        |
| Gleason biopsy score       |                               |                                   |                   |
| <7                         | 345 (16.2)                    | 70 (8.8)                          | 415 (14.2)        |
| 7                          | 1225 (57.5)                   | 469 (58.6)                        | 1,694 (57.8)      |
| >7                         | 560 (26.3)                    | 261 (32.6)                        | 821 (28.0)        |
| Clinical T-stage           |                               |                                   |                   |
| T1                         | 259 (12.6)                    | 50 (7.5)                          | 309 (11.4)        |
| T2                         | 1260 (61.5)                   | 241 (36.0)                        | 1,501 (55.2)      |
| T3-T4                      | 529 (25.8)                    | 378 (56.5)                        | 907 (33.4)        |
| Comorbidity*               |                               |                                   |                   |
| Cardiovascular diseases    | 118 (5.5)                     | 52 (6.4)                          | 170 (5.8)         |
| Other malignancies         | 102 (4.7)                     | 64 (7.9)                          | 166 (5.6)         |
| Diabetes                   | 62 (2.9)                      | 48 (6.0)                          | 110 (3.7)         |
| Charlson comorbidity index |                               |                                   |                   |
| 1                          | 267 (12.4)                    | 115 (14.3)                        | 382 (12.9)        |
| >1                         | 203 (9.4)                     | 107 (13.3)                        | 310 (10.4)        |


Characteristics on the day of surgery for men with high-risk prostate cancer from 2011 to 2018. Percentages may not add up to 100 due to rounding or missing data. \*Top 3 comorbidities. Abbreviations: IQR, interquartile range; PSA, prostate specific antigen; T-stage, tumour stage.

Study cohort of 2,161 men undergoing presurgical imaging with bone scintigraphy and 807 men undergoing 18F-NaF PET.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41




The unadjusted cumulative incidence with 95% confidence intervals of SREs in men after undergoing radical prostatectomy. Death was treated as a competing event. The red curve represents <sup>18</sup>F-NaF PET, and the black curve represents bone scintigraphy.






1 **Figure 3. Main analysis results**

2 Hazard ratios for SREs following radical prostatectomy among patients undergoing  $^{18}\text{F}$ -NaF  
 3 PET before surgery versus patients undergoing bone scintigraphy.  
 4



Unadjusted cumulative incidence of death with 95% confidence intervals for men with prostate cancer after undergoing radical prostatectomy, stratified by type of imaging modality. The red curve represents 18F-NaF PET, and the black curve represents bone scintigraphy.



## APPENDIX 1

**Table 1.** Registry data used in the analysis.


| Registry  | Code      |
|---|-----------|
| The Danish Cancer Registry                          |           |
| ICD-10 diagnosis and morphologic codes              |           |
| Prostate cancer                                     | DC61.9    |
| Tumor stage   | TNM       |
| The Danish National Registry of Patients            |           |
| Imaging modality                                    |           |
| Danish Health Care Classification System, sks-codes |           |
| Bone scintigraphy                                   | WKBxx     |
| <sup>18</sup> F-NaF PET                             | WDTPSFCXX |
| The Danish National Registry of Patients            |           |
| Primary prostate cancer treatment                   |           |
| NCSP codes  |           |
| Radical prostatectomy                               | KKECxx    |
| The Danish National Registry of Patients            |           |
| Skeletal-related events                             |           |
| NCSP codes  |           |
| Radiation to bone                                   | BWGxx     |
| Surgery to bone                                     | KNAGxx    |
| ICD-10 codes  |           |
| Bone metastases                                     | DC79.5    |
| Spinal cord compression                             | DG952     |
| Pathological fractures                              |           |
| Osteoporotic fractures                              |           |
| The Danish Register of Laboratory Results           |           |
| NPU codes   |           |
| PSA   | NPU0866   |
| The Danish National Pathology Registry              |           |
| SNOMED codes  |           |
| Gleason score                                       | ÆF0xx     |

NCSP: Nomesco Classification of Surgical Procedures; NPU: Nomenclature for Properties and Units; SNOMED: Systematized Nomenclature of Medicine


**Table 2.** Comorbidity codes from The Danish National Patient Registry used to calculate the Charlson Comorbidity Index. All codes are ICD-10 codes.

| Comorbidity                    | Code   |
|--------------------------------|--|
| Myocardial infarction          | DI21, DI22   |
| Heart failure                  | DI099, DI110, DI130, DI132, DI255, DI425, DI426, DI427, DI429, DI428A, DP290, DI43, DI50, DE105, DE115, DE125, DE135, DE145  |
| Peripheral vascular disease    | DI70, DI71, DI72, DI731, DI738, DI739, DI77, DI790, DI792, DK551, DK558, DK559, DZ958, DZ959   |
| Cerebrovascular disease        | DI60, DI61, DI62, DI63, DI64, DI65, DI66, DI67, DI68, DI69, DG45, DG46, DH340  |
| Dementia                       | DF00, DF01, DF02, DF03, DG30, DF051, DG311   |
| Chronic pulmonary disease      | DJ40, DJ41, DJ42, DJ43, DJ44, DJ45, DJ46, DJ47, DJ60, DJ61, DJ62, DJ63, DJ64, DJ65, DJ66, DJ67, DJ684, DI278, DI279, DJ84, DJ701, DJ703, DJ920, DJ953, DJ961, DJ982, DJ983   |
| Rheumatic disease              | DM05, DM06, DM08, DM09, DM30, DM31, DM32, DM33, DM34, DM35, DM35, DM36, D86  |
| Peptic ulcer disease           | DK25, DK26, DK27, DK28, DK221  |
| Mild liver disease             | DB18, DK700, DK701, DK702, DK709, DK703, DK713, DK714, DK715, DK717, DK73, DK74, DK760, DK762, DK763, DK764, DK769, DZ944  |
| Severe liver disease           | DB150, DB160, DB162, DB190, DI850, DI859, DI864, DI982, DK704, DK711, DK721, DK729, DK765, DK766, DK767  |
| Diabetes without complications | DE100, DE101, DE108, DE109, DE110, DE111, DE119, DE120, DE121, DE129, DE130, DE131, DE139, DE140, DE141, DE149   |
| Diabetes with complications    | DE102, DE103, DE104, DE105, DE106, DE107, DE112, DE113, DE114, DE115, DE116, DE117, DE118, DE122, DE123, DE124, DE125, DE126, DE127, DE128, DE132, DE133, DE134, DE135, DE136, DE137, DE138, DE142, DE143, DE144, DE145, DE146, DE147, DE148 |
| Hemiplegia paraplegia          | DG830, DG831, DG832, DG833, DG834, DG81, DG82, DG041, DG114, DG801, DG802, DG839   |
| Renal disease                  | DN032, DN033, DN034, DN035, DN036, DN037, DN052, DN053, DN054, DN055, DN056, DN057, DZ490, DZ491, DZ492, DN18, DN19, DI120, DI131, DI132, DN250, DZ940, DZ992, DN26  |
| Any malignancy                 | DC0, DC1, DC2, DC3, DC40, DC41, DC42, DC43, DC44, DC45, DC46, DC47, DC48, DC49, DC5, DC6, DC70, DC71, DC72, DC73, DC74, DC75, DC76, DC86, DC97   |
| Metastatic solidtumor          | DC77, DC78, DC79, DC80   |
| AIDS/HIV                       | DB20, DB21, DB22, DB23, DB24   |
| Leukemia                       | DC91, DC92, DC93, DC94, DC95   |
| Lymphoma                       | DC81, DC82, DC83, DC84, DC85, DC88, DC90, DC96   |

**Figure 1.** Unadjusted cumulative incidence with 95% confidence interval of skeletal-related events (SRE) in men after undergoing radical prostatectomy, restricted to men from the Capitol region of Denmark. Death was treated as a competing event. Red curve represents  $^{18}\text{F}$ -NaF PET, black curve bone scintigraphy.



**Figure 2.** Hazard ratios for skeletal-related events following radical prostatectomy among patients receiving a <sup>18</sup>F-NaF PET before surgery compared with patients receiving a bone scintigraphy. Restricted to the Capitol region of Denmark.



Peer review only

**Table 3.** Demographics for the Capitol region of Denmark. Baseline characteristics on the day of surgery for men with high-risk prostate cancer from 2011-2018\* Stratified by pre-surgery imaging.

|                            | <b>Bone scintigraphy (n=690)</b> | <b><sup>18</sup>F-NaF PET (n=740)</b> | <b>All (n=1,430)</b> |
|----------------------------|----------------------------------|---------------------------------------|----------------------|
| Age (year, median (IQR))   | 66.2 (60.8, 69.3)                | 67.9 (62.9, 71.1)                     | 66.9 (61.9, 70.1)    |
| Year of surgery            |                                  |                                       |                      |
| 2011-2013                  | 331 (48.0)                       | 212 (28.6)                            | 543 (38.0)           |
| 2014-2015                  | 185 (26.8)                       | 231 (31.2)                            | 416 (29.1)           |
| 2016-2018                  | 174 (25.2)                       | 297 (40.1)                            | 471 (32.9)           |
| PSA (ng/mL)                |                                  |                                       |                      |
| <10                        | 300 (44.1)                       | 250 (34.4)                            | 550 (39.1)           |
| 10-20                      | 229 (33.6)                       | 271 (37.3)                            | 500 (35.5)           |
| >20                        | 152 (22.3)                       | 206 (28.3)                            | 358 (25.4)           |
| Gleason score              |                                  |                                       |                      |
| <7                         | 81 (12.0)                        | 61 (8.3)                              | 142 (10.1)           |
| 7                          | 401 (59.6)                       | 432 (58.9)                            | 833 (59.2)           |
| >7                         | 191 (28.4)                       | 240 (32.7)                            | 431 (30.7)           |
| Clinical T-stage           |                                  |                                       |                      |
| T1                         | 58 (9.0)                         | 39 (6.3)                              | 97 (7.7)             |
| T2                         | 435 (67.3)                       | 220 (35.8)                            | 655 (51.9)           |
| T3-T4                      | 153 (23.7)                       | 356 (57.9)                            | 509 (40.4)           |
| Comorbidity                |                                  |                                       |                      |
| Cardiovascular diseases    | 35 (5.1)                         | 46 (6.2)                              | 81 (5.7)             |
| Other malignancies         | 29 (4.2)                         | 59 (8.0)                              | 88 (6.2)             |
| Diabetes                   | 21 (3.0)                         | 44 (6.0)                              | 65 (4.6)             |
| Charlson comorbidity index |                                  |                                       |                      |
| 1                          | 84 (12.2)                        | 103 (13.9)                            | 187 (13.1)           |
| >1                         | 59 (8.6)                         | 97 (13.1)                             | 156 (10.9)           |

\*Percentages may not sum to 100 due to rounding or missing data

IQR: Interquartile range; PSA: Prostate specific antigen; T-stage: Tumor stage.

## STROBE (Strengthening The Reporting of OBServational Studies in Epidemiology) Checklist

A checklist of items that should be included in reports of observational studies. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

| Section and Item     | Item No. | Recommendation   | Reported on Page No. |
|----------------------|----------|--|----------------------|
| Title and Abstract   | 1        | (a) Indicate the study's design with a commonly used term in the title or the abstract   |                      |
|                      |          | (b) Provide in the abstract an informative and balanced summary of what was done and what was found  |                      |
| <b>Introduction</b>  |          |  |                      |
| Background/Rationale | 2        | Explain the scientific background and rationale for the investigation being reported   |                      |
| Objectives           | 3        | State specific objectives, including any prespecified hypotheses   |                      |
| <b>Methods</b>       |          |  |                      |
| Study Design         | 4        | Present key elements of study design early in the paper  |                      |
| Setting              | 5        | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection  |                      |
| Participants         | 6        | (a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up<br><br><i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls<br><br><i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants |                      |
|                      |          | (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed<br><br><i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case   |                      |
| Variables            | 7        | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable   |                      |



| Section and Item             | Item No. | Recommendation  | Reported on Page No. |
|------------------------------|----------|---|----------------------|
| Data Sources/<br>Measurement | 8*       | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group  |                      |
| Bias                         | 9        | Describe any efforts to address potential sources of bias   |                      |
| Study Size                   | 10       | Explain how the study size was arrived at   |                      |
| Quantitative Variables       | 11       | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why  |                      |
| Statistical Methods          | 12       | (a) Describe all statistical methods, including those used to control for confounding   |                      |
|                              |          | (b) Describe any methods used to examine subgroups and interactions   |                      |
|                              |          | (c) Explain how missing data were addressed   |                      |
|                              |          | (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed<br><i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed<br><i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy |                      |
|                              |          | (e) Describe any sensitivity analyses   |                      |
| <b>Results</b>               |          |   |                      |
| Participants                 | 13*      | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed   |                      |
|                              |          | (b) Give reasons for non-participation at each stage  |                      |
|                              |          | (c) Consider use of a flow diagram  |                      |
| Descriptive Data             | 14*      | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders  |                      |
|                              |          | (b) Indicate number of participants with missing data for each variable of interest   |                      |
|                              |          | (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)  |                      |
| Outcome Data                 | 15*      | <i>Cohort study</i> —Report numbers of outcome events or summary measures over time   |                      |
|                              |          | <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure  |                      |
|                              |          | <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures  |                      |

| Section and Item         | Item No. | Recommendation   | Reported on Page No. |
|--------------------------|----------|--|----------------------|
| Main Results             | 16       | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included |                      |
|                          |          | (b) Report category boundaries when continuous variables were categorized  |                      |
|                          |          | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   |                      |
| Other Analyses           | 17       | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses   |                      |
| <b>Discussion</b>        |          |  |                      |
| Key Results              | 18       | Summarise key results with reference to study objectives   |                      |
| Limitations              | 19       | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias   |                      |
| Interpretation           | 20       | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                                   |                      |
| Generalisability         | 21       | Discuss the generalisability (external validity) of the study results  |                      |
| <b>Other Information</b> |          |  |                      |
| Funding                  | 22       | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based  |                      |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.**

# BMJ Open

## USE OF 18F-NaF-PET IN THE STAGING OF SKELETAL METASTASES OF NEWLY DIAGNOSED, HIGH-RISK PROSTATE CANCER PATIENTS - A NATIONWIDE COHORT STUDY.

|                                 |  |
|---------------------------------|--|
| Journal:                        | <i>BMJ Open</i>  |
| Manuscript ID                   | bmjopen-2021-058898.R1   |
| Article Type:                   | Original research  |
| Date Submitted by the Author:   | 19-Apr-2022  |
| Complete List of Authors:       | Mogensen, Anna Winther; Aalborg University Hospital, Department of Nuclear Medicine<br>Petersen, Lars J; Aalborg University Hospital, Department of Nuclear Medicine; Aalborg University, Department of Clinical Medicine<br>Torp-Pedersen, Christian; Nordsjællands Hospital<br>Nørgaard, Mette; Aarhus University Hospital, Department of Clinical Epidemiology<br>Pank, Marie T; Aalborg University Hospital, Department of Urology<br>Zacho, Helle; Aalborg University Hospital, Department of Nuclear Medicine; Aalborg University, Department of Clinical Medicine |
| <b>Primary Subject Heading</b>: | Oncology   |
| Secondary Subject Heading:      | Urology, Epidemiology, Oncology  |
| Keywords:                       | NUCLEAR MEDICINE, ONCOLOGY, Epidemiology < ONCOLOGY, Urological tumours < UROLOGY  |
|                                 |  |

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# TITLE PAGE

## USE OF $^{18}\text{F}$ -NaF-PET IN THE STAGING OF SKELETAL METASTASES OF NEWLY DIAGNOSED, HIGH-RISK PROSTATE CANCER PATIENTS - A NATIONWIDE COHORT STUDY.

### Corresponding author

PhD student, Anna W Mogensen, MSc  
Department of Nuclear Medicine  
Aalborg University Hospital  
Hobrovej 18-22, 9000 Aalborg, Denmark  
E-mail: [anna.w@rn.dk](mailto:anna.w@rn.dk)  
Tlf. +45 2876 6353

### Co-Authors

Professor Emeritus, Lars J Petersen, MD, DMSc  
Department of Nuclear Medicine  
Aalborg University Hospital, Denmark  
[lars.jelstrup.petersen@gmail.com](mailto:lars.jelstrup.petersen@gmail.com)

Professor, Christian Torp-Pedersen, MD, DMSc  
Department of Clinical Investigations and Department of Cardiology  
Nordsjaellands Hospital, Denmark  
[christian.torp-pedersen.01@regionh.dk](mailto:christian.torp-pedersen.01@regionh.dk)

Professor, Mette Nørgaard, MD, PhD  
Department of Clinical Epidemiology  
Aarhus University Hospital, Denmark  
[mn@clin.au.dk](mailto:mn@clin.au.dk)

Chief Physician, Marie T Pank, MD  
Department of Urology  
Aalborg University Hospital, Denmark  
[mtp@rn.dk](mailto:mtp@rn.dk)

Associate Professor, Helle D Zacho, MD, PhD  
Department of Nuclear Medicine  
Aalborg University Hospital, Denmark  
[h.zacho@rn.dk](mailto:h.zacho@rn.dk)

**Word count (introduction, methods, results, discussion): 3234**

1  
2  
3  
4 1 **USE OF <sup>18</sup>F-NaF-PET IN THE STAGING OF SKELETAL METASTASES OF NEWLY**  
5 **DIAGNOSED, HIGH-RISK PROSTATE CANCER PATIENTS - A NATIONWIDE COHORT**  
6 2 **STUDY.**  
7 3  
8 4  
9 4

10 5 Anna W Mogensen<sup>1</sup>, Lars J Petersen<sup>1,2</sup>, Christian Torp-Pedersen<sup>3</sup>, Mette Nørgaard<sup>4</sup>, Marie T Pank<sup>5</sup>, Helle D  
11 6 Zacho<sup>1,2</sup>

12 7 <sup>1</sup>Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University  
13 8 Hospital, Aalborg, Denmark, <sup>2</sup>Department of Clinical Medicine, Aalborg University, Aalborg  
14 9 Denmark, <sup>3</sup>Department of Clinical Investigations and Department of Cardiology, Nordsjaellands Hospital,  
15 10 Denmark, <sup>4</sup>Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark,  
16 11 <sup>5</sup>Department of Urology, Aalborg University Hospital, Aalborg, Denmark.  
17 12  
18 13  
19 14  
20 15  
21 16  
22 17  
23 18  
24 19  
25 20  
26 21  
27 22  
28 23  
29 24  
30 25  
31 26  
32 27  
33 28  
34 29  
35 30  
36 31  
37 32  
38 33  
39 34  
40 35  
41 36  
42 37  
43 38  
44 39  
45 40  
46 41  
47 42  
48 43  
49 44  
50 45  
51 46  
52 47  
53 48  
54 49  
55 50  
56 51  
57 52  
58 53  
59 54  
60 55

44 27 **Corresponding author**

45 28 Anna W Mogensen

46 29 Dept. of Nuclear Medicine

47 30 Aalborg University Hospital

48 31 Hobrovej 18-22, Postboks 365

49 32 DK-9100 Aalborg, Denmark

50 33 Tel: +45 2876 6353

51 34 E-mail: [anna.w@rn.dk](mailto:anna.w@rn.dk)

1  
2  
3  
4 **1 ABSTRACT**

5  
6 **2 Objective** To determine whether preoperative staging of high-risk prostate cancer with  $^{18}\text{F}$ -NaF PET reduces  
7  
8  
9 the risk of skeletal metastases.

10 **4 Design** Nationwide, population-based cohort study using real-world data.

11  
12 **5 Setting** The study used national health registries, including all sites in Denmark from 2011-2018.

13  
14 **6 Participants** Newly diagnosed high-risk prostate cancer patients who underwent radical prostatectomy from  
15  
16  
17  
18  
19 2011-2018. Patients were stratified into two groups according to the preoperative imaging modality of either  
20  
21  
22  $^{18}\text{F}$ -NaF PET or bone scintigraphy.

23  
24 **9 Main outcome measures** The risk of skeletal-related events as a proxy for skeletal metastases following  
25  
26  
27  
28  
29  
30  
31  
32 radical prostatectomy. The secondary endpoint was overall survival.

33  
34  
35 **11 Results** Between January 1, 2011, and December 31, 2018, 4,183 high-risk patients underwent radical  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
21

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 STRENGTHS AND LIMITATIONS OF THIS STUDY

- 2 - Registry data provides real-world data on the clinical impact of clinical practices
- 3 - This study identified a large cohort from all institutions in Denmark using high-quality registry data.
- 4 - The routinely collected health data are not specifically registered for the purposes of this research, resulting  
5 in a minor degree of missing data.
- 6 - Regression analysis weighted by the inverse probability of treatment ensured consideration of all measured  
7 confounders and addressed confounding by indication.

For peer review only



## 1 INTRODUCTION

2 Prostate cancer is one of the most common malignancies in the Western world, with over 1.4 million new cases  
3 reported in 2020.<sup>1</sup> Prostate cancer frequently metastasizes to the bone, which is associated with significant  
4 morbidity and mortality.<sup>2,3</sup> Accurate detection of bone metastases at primary staging is essential for decision-  
5 making regarding subsequent management. At the time of diagnosis, the risk of recurrence is determined based  
6 on the PSA level, Gleason score, and clinical tumour stage (T-stage).<sup>4</sup> Patients classified as unfavorable-  
7 intermediate risk or high risk will often receive preoperative staging by imaging. International urology and  
8 oncology guidelines recommend bone scintigraphy with 99mTechnetium-labeled phosphonate (99mTc) for  
9 the assessment of bone metastases at primary staging.<sup>4,5</sup>

10 However, several studies have shown that the bone-specific positron emission tomography (PET) tracer <sup>18</sup>F-  
11 sodium-fluoride (<sup>18</sup>F-NaF) is superior to bone scintigraphy in terms of its diagnostic accuracy for detecting  
12 bone metastases including fewer equivocal findings.<sup>6-8</sup> In previous studies, the sensitivity of bone scintigraphy  
13 for the detection of bone metastases varied from 57% to 97%, and the specificity varied from 57 to 80%.<sup>6-9</sup> In  
14 contrast, the sensitivity of <sup>18</sup>F-NaF PET for the diagnosis of bone metastases has ranged from 81 to 100% in  
15 the majority of studies, with a specificity ranging from 71 to 100%.<sup>6-8,10,11</sup> With the purported lower accuracy  
16 of bone scintigraphy, the risk of misdiagnosing patients is high, possibly resulting in suboptimal treatment  
17 strategies. Among patients referred for suspected metastases, the use of <sup>18</sup>F-NaF PET instead of bone  
18 scintigraphy in patients with prostate cancer has been shown to affect the patient management strategy in 6-  
19 12% of cases.<sup>12,13</sup> However, no studies have documented that the subsequent change in patient management  
20 strategies induced by <sup>18</sup>F-NaF PET and its improved diagnostic accuracy confer any patient benefit in terms of  
21 mortality, morbidity and quality of life. Thus, we performed a cohort study with real-world data of men  
22 diagnosed with prostate cancer in Denmark who underwent either bone scintigraphy or <sup>18</sup>F-NaF PET as part  
23 of primary staging before curative intent prostatectomy to examine whether the type of preoperative imaging  
24 modality was associated with overall survival and skeletal-related events (SREs) after radical prostatectomy.

## 1 2 3 4 1 **METHODS**

### 5 6 2 **Study Population and Data Sources**

7 3 This nationwide register-based cohort study was conducted in Denmark, which has approximately 5.8 million  
8 4 residents. In Denmark, all residents are provided with free, tax-supported health care by the National Health  
9 5 Service. A unique 10-digit civil registration number is assigned to all residents at birth by the Central Office  
10 6 of Civil Registration. This number allows unambiguous linkage across all Danish population-based registries.<sup>14</sup>  
11 7 Reporting to the registries by clinicians is mandatory, which ensures high completeness of medical  
12 8 information. The applied data included nationwide information from the Danish Cancer Registry,<sup>15</sup> the Civil  
13 9 Registration System,<sup>16</sup> the Danish National Patient Registry,<sup>17</sup> the Register of Laboratory Results for  
14 10 Research,<sup>18</sup> the Danish Prostate Cancer Database,<sup>19</sup> the Danish National Pathology Register,<sup>20</sup> and the Register  
15 11 of Causes of Death.<sup>21</sup> Appendix 1 (p 1) provides a detailed description of the codes found in the registries for  
16 12 prostate cancer characteristics, treatment, outcomes, and covariates. Furthermore, the study is reported in  
17 13 accordance with STROBE guidelines, and a checklist is provided in the supplementary files.

### 18 19 20 21 22 23 24 25 14 **Identifying Men with Prostate Cancer**

26 15 No formal screening program for prostate cancer existed during the study period. Therefore, men were referred  
27 16 to the urology department upon suspicion of prostate cancer. We used the Danish National Patient Registry to  
28 17 identify a cohort consisting of men with a first-time prostate cancer diagnosis from 2011 through 2018 who  
29 18 had undergone radical prostatectomy. This registry was established in 1977 for hospitalized patients; outpatient  
30 19 visits at hospitals have been included since 1995.<sup>17</sup> The registry includes dates of admission and discharge,  
31 20 diagnosis (ICD-10 codes), surgical procedures, and treatment information. The validity of a prostate cancer  
32 21 diagnosis in this register has previously been evaluated and found to be high, with a positive predictive value  
33 22 of nearly 90%.<sup>22</sup>

### 34 35 36 37 38 39 40 23 **Risk Classification**

41 24 We restricted the cohort to patients we could classify as having a preoperative high risk of cancer recurrence  
42 25 according to the European Association of Urology (EAU) risk classification of prostate cancer. The EAU  
43 26 defines high-risk patients as those with a PSA of more than 20 ng/mL OR a Gleason score >7 OR a T-stage of  
44 27 T2c as the minimum.<sup>4</sup> PSA values were retrieved from the Danish Register of Laboratory Results, which  
45 28 includes laboratory data from four of the five regions of Denmark.<sup>18</sup> Data from the last region were obtained  
46 29 directly from the relevant regional database. The Gleason score was obtained from the Pathology Register,  
47 30 which contains information on all pathological examinations conducted in Denmark since 1997. T-stage was  
48 31 obtained from the Danish Cancer Registry, which has prospectively recorded all cancers diagnosed in Denmark  
49 32 since 1943, classified according to ICD-10, and ICD Oncology codes (ICD-O-3) for topography and  
50 33 morphology.<sup>15</sup> For all three variables, we included the latest recorded value within six months prior to surgery.  
51 34 If PSA, Gleason score, or T-stage were missing, we used the Danish Prostate Cancer Database to fill in the  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 1 missing variables. This register is a nationwide clinical cancer database established in 2010 that records data  
5  
6 2 on all incident, historically verified prostate cancer cases.

### 8 3 **Imaging Modality**

9  
10 4 We retrieved information on imaging modalities from the Danish National Patient Registry. We identified the  
11 5 preoperative use of bone scintigraphy and  $^{18}\text{F}$ -NaF PET, recorded up to 6 months before surgery, combined  
12 6 with computer tomography (CT) or magnetic resonance imaging (MRI). Single-photon emission (SPECT)/CT  
13 7 was conducted according to institutional practices. Patients were categorized according to their preoperative  
14 8 imaging into two groups: those who underwent bone scintigraphy only (bone scintigraphy group) and those  
15 9 who underwent  $^{18}\text{F}$ -NaF PET scan with or without bone scintigraphy ( $^{18}\text{F}$ -NaF PET group). In general, each  
16 10 site performed only one of the two scans; thus, physicians did not stratify patients according to a specific  
17 11 imaging modality. Patients with an  $^{18}\text{F}$ -NaF PET scan performed as a part of a clinical research project were  
18 12 excluded from the cohort because the results of these scans were not made available to the referring physician.

### 24 13 **SREs and Bone Metastases**

25 14 We obtained information on SREs through the Danish National Patient Registry. SREs comprised the  
26 15 following events occurring after the date of radical prostatectomy: radiation to the bone defined as 1-4  
27 16 treatments with external radiation therapy (standard practice in Denmark for the treatment of bone pain),  
28 17 pathological and osteoporotic fractures, spinal cord compression, surgery to the bone, or a first-time bone  
29 18 metastasis diagnosis code.

### 35 19 **Mortality**

36 20 Mortality and migration updates were obtained from the Civil Registration System, which is updated daily.<sup>14</sup>  
37 21 The register contains information on the vital status (dead or alive), date of death, and migration status of all  
38 22 Danish citizens.

### 42 23 **Comorbidity**

43 24 We used the Charlson comorbidity index to describe preexisting comorbidities in the prostate cancer cohort<sup>23</sup>  
44 25 (appendix 1 p 2). We calculated the index based on diagnoses recorded in the Danish National Patient Registry  
45 26 up to ten years before the date of surgery. For analysis, we categorized the index into 3 comorbidity levels,  
46 27 including 1) those without comorbidity, 2) those with a comorbidity index equal to 1, and 3) those with a  
47 28 comorbidity index above 1.

### 52 29 **Statistical Analysis**

53 30 Baseline characteristics are reported as frequencies with percentages and medians with interquartile ranges.  
54 31 We estimated the cumulative risk of SREs according to the type of imaging modality and plotted the  
55 32 cumulative risk as a function of time since radical prostatectomy; death was treated as a competing risk event.  
56 33 Patients contributed time at risk from the date of radical prostatectomy until the date of first-time registered  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 SRE, migration, death, or December 31, 2018, whichever came first. Finally, we similarly estimated the  
2 cumulative incidence of death.

3 For the main analysis, we used Cox proportional hazards regression analysis to estimate the age-adjusted and  
4 multivariate-adjusted hazard ratios (HRs) of SREs with 95% CIs, comparing those who underwent <sup>18</sup>F-NaF  
5 PET scans with those who underwent bone scintigraphy. Additionally, to better control potential confounding  
6 by indication, analysis of the inverse probability of treatment weighting (IPTW) was performed based on the  
7 propensity score for <sup>18</sup>F-NaF PET. Propensity scores were calculated using logistic regression with the  
8 inclusion of the same variables as in the adjusted Cox analysis. We adjusted for age, Charlson comorbidity  
9 index, PSA (categorical variable: <10, 10-20, >20 ng/mL), Gleason score (categorical variable: <7, 7, >7), and  
10 T-stage (categorical variable: T1, T2, T3+T4). Adjusting with categorical variables was deemed necessary due  
11 to outliers and the limited number of records available on the outer areas of the scales. Furthermore, we  
12 stratified the analysis by PSA, Gleason score, T-stage, and year of radical prostatectomy. In the stratified  
13 analysis, we only adjusted for age and Charlson comorbidity index. An adjusted HR of death was also  
14 calculated. No further analyses were performed for patients with other types of imaging or no imaging before  
15 surgery.

16 Several sensitivity analyses were performed to test the robustness of our findings. First, due to potential site-  
17 related differences in risk factors among the included patients, we conducted an analysis restricted to the capitol  
18 region of Denmark, which performed most of the <sup>18</sup>F-NaF PET scans. Second, we executed the analysis with  
19 a reclassification of the exposure group to include patients with both scans. To account for missing data and  
20 enable adjustment for PSA, Gleason score, and T-stage we used multiple imputation using splines<sup>24</sup> with all  
21 the main analysis variables and the outcome variable in the model. We produced and combined 200 sets of  
22 imputations.

### 23 **Statistical software**

24 Data management and analyses were conducted in R 4.0.3 using RStudio 2020 (RStudio, PBC, Boston, MA)  
25 with the following packages: heaven, data.table, Publish, survival, stringr, mitools, smcfcs and ipw.

### 26 **Ethics Approval**

27 The Danish Data Protection Agency approved the use of data for this study (reference number 2008-58-0028).  
28 Furthermore, the study was granted approval by the Danish Patient Safety Authority to collect laboratory data  
29 (reference numbers 3-3013-3183/1 and 31-1522-37). Ethics approval is not required for historical register-  
30 based studies in Denmark.

1  
2  
3  
4 **1 Patient and public involvement**

5  
6 2 This study was observational and based on data from routine healthcare records. No patients were directly  
7 3 involved in the study.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## 1 RESULTS

2 Between January 1, 2011, and December 31, 2018, 36,910 men were diagnosed with prostate cancer in  
3 Denmark, of whom 8,726 (23.6%) underwent radical prostatectomy (Figure 1). Among those who underwent  
4 radical prostatectomy, 4,183 patients (47.9%) were classified as high risk according to the EAU preoperative  
5 staging criteria. A total of 2,161 (51.7%) high-risk patients undergoing surgery were evaluated for skeletal  
6 metastasis with bone scintigraphy only, and 807 (19.3%) men were evaluated with  $^{18}\text{F}$ -NaF PET. Information  
7 on the PSA values, Gleason score, and T-stage from the registries ensured nearly 90% completeness of the  
8 high-risk classification, resulting in a large study population for our analysis. A notable proportion of high-  
9 risk patients (28.5%) underwent different imaging modalities or no imaging to evaluate bone metastasis, and  
10 a small portion of patients (0.5%) were excluded because they underwent project-related imaging. The median  
11 age at the date of radical prostatectomy was 67 years (interquartile range, 62-70.1), and the median follow-up  
12 from surgery was 4.1 years (interquartile range, 2.4-6.0 years). In general, patients receiving  $^{18}\text{F}$ -NaF PET had  
13 a higher PSA level, Gleason score, and T-stage at primary staging (Table 1).

### 14 SREs and Bone Metastases

15 The unadjusted one-year cumulative risk of SREs was 2.4% (95% CI 1.8-3.1) for men who underwent bone  
16 scintigraphy and 4.3% (95% CI 2.8-5.7) for those who underwent  $^{18}\text{F}$ -NaF PET (Figure 2). The unadjusted 3-  
17 year cumulative risk of SREs was 7.2% (95% CI 6.0-8.3) for men undergoing bone scintigraphy and 11.9%  
18 (95% CI 9.4-14.4) for those undergoing  $^{18}\text{F}$ -NaF PET. Of the 300 men with at least one SRE recorded during  
19 follow-up, 53.7% had radiation to bone recorded as their first event, 30.7% had a pathological or osteoporotic  
20 fracture, 6.3% had spinal cord compression, 6.3% had a code for bone metastases, and 3.0% had bone surgery.  
21 In the main analysis, we did not find that  $^{18}\text{F}$ -NaF PET decreased the HR of experiencing SREs after surgery;  
22 in contrast, we observed a slightly increased HR, which was reduced when adjusting the model (adjusted HR,  
23 1.22; 95% CI 0.93-1.61; Figure 3). When we used IPTW to control for potential confounding factors, the risk  
24 of experiencing an SRE was attenuated (IPTW adjusted HR, 1.15; 95% CI 0.86-1.54; Figure 3). Stratified  
25 analyses similarly demonstrated increased HRs for SREs in patients undergoing  $^{18}\text{F}$ -NaF PET compared to  
26 those undergoing bone scintigraphy, except for patients with stage 2 disease and those with a Gleason score  
27 <7 (Figure 3).

### 28 Survival

29 Figure 4 shows the cumulative survival curves of the cohorts for up to 7 years of follow-up. The one-year  
30 survival was 99.4% (95% CI 99.0-99.7) in men who underwent bone scintigraphy and 99.5% (95% CI 98.9-  
31 100) in men who underwent  $^{18}\text{F}$ -NaF PET, and the corresponding 3-year survival rates in the cohorts were  
32 97.1% (95% CI 96.4-97.9) and 97.4% (95% CI 96.1-98.7), respectively. Adjusted analyses showed a modest  
33 reduction in mortality for patients who underwent  $^{18}\text{F}$ -NaF PET (adjusted HR, 0.89; 95% CI 0.61-1.30).



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 DISCUSSION

### 2 Principal findings

3 In this nationwide cohort study of Danish patients with high-risk prostate cancer undergoing prostatectomy,  
4 we found that primary staging with  $^{18}\text{F}$ -NaF PET did not reduce the risk of SREs compared to primary staging  
5 with bone scintigraphy, whereas a slight tendency towards a reduction in all-cause mortality was observed in  
6 the group undergoing  $^{18}\text{F}$ -NaF PET. To the best of our knowledge, this is the first study to evaluate patient-  
7 relevant outcomes of using a PET-based method for primary staging.

### 8 Comparison with other studies

9 Prior studies on  $^{18}\text{F}$ -NaF PET in prostate cancer have focused on its improvements in diagnostic accuracy  
10 compared to bone scintigraphy<sup>6-8</sup> or its impact on patient management.<sup>12 13</sup> The superior diagnostic  
11 performance of  $^{18}\text{F}$ -NaF PET when detecting bone metastases, should presumably result in improved patient  
12 selection for curative and life-prolonging treatment, resulting in fewer SREs the first few years after surgery.  
13 However, in this study, we did not observe any superiority over bone scintigraphy in terms of patient benefit  
14 among newly diagnosed, high-risk prostate cancer patients.

15 Evidence of patient-relevant outcomes is often reported from randomized controlled trials. Randomized trials  
16 are, however, not commonly conducted within the field of imaging, and it has previously been debated whether  
17 randomized trials are necessary to evaluate diagnostic procedures.<sup>25 26</sup> In prostate cancer, only two randomized  
18 controlled trials have been published, employing PET in one arm and standard imaging in the other arm. One  
19 such trial confirmed the diagnostic superiority of PSMA PET/CT during primary staging<sup>27</sup>, whereas the other  
20 trial focused on the changes in patient management based on fluciclovine PET/CT at the time of biochemical  
21 recurrence;<sup>28</sup> none of these trials were linked to patient-relevant outcomes.

22 Randomized trials have demonstrated the clinical benefit of PET within other types of cancers, such as  
23 haematological and lung cancers.<sup>29</sup> Fischer et al. compared preoperative staging with FDG PET/CT to  
24 conventional staging by CT in lung cancer patients and found that patients in the PET/CT group showed a  
25 reduction in both the total number of thoracotomies and the number of futile thoracotomies; however, they did  
26 not observe a decrease in overall mortality.<sup>30</sup> Similar results were reported for colorectal liver metastases, with  
27 one study finding that FDG PET led to a reduction in futile laparotomies in 1 of 6 patients.<sup>31</sup> It could be  
28 expected that the use of  $^{18}\text{F}$ -NaF PET would reduce the number of “futile” prostatectomies in patients  
29 harbouring bone metastases at the time of diagnosis, thereby reducing the incidence of SREs postoperatively.  
30 With recent trials demonstrating superior diagnostic properties of PSMA PET for primary staging in high-risk  
31 prostate cancer, its impact on treatment choice—and perhaps outcome—is likely to be greater than that of  $^{18}\text{F}$ -  
32 NaF PET.



## 1 Strengths and limitations

2 The major strengths of our study are its national scale, large cohort, high-quality registry data, and complete  
3 follow-up. The registration of information related to prostate cancer diagnosis and radical prostatectomy, as  
4 well as variables defining the high-risk population, is thought to be practically complete because of a uniformly  
5 organized health care system where healthcare is free (tax-supported) and available to all residents.<sup>32</sup>  
6 Furthermore, a median follow-up time of 4.1 years is adequate for the purpose of evaluating bone metastases  
7 not captured by the imaging modality at primary staging; hence, only patients with a negative scan will undergo  
8 radical prostatectomy with curative intent in Denmark.

9 Nevertheless, our study has several limitations worth considering. The potential of confounding by indication  
10 was particularly concerning because of the observed higher values for PSA, Gleason score, and T-stage in the  
11 <sup>18</sup>F-NaF PET group; however, the indication of usage was the same for both scans. Moreover, the  
12 demographics of the groups might have been more alike if the International Society of Urological  
13 Pathology (ISUP) grading system was used for the Gleason score, which distinguishes between normal high-  
14 risk prostate cancer and very high-risk (ISUP grade 5) cancer cases. It was not possible to use the ISUP grading  
15 due to unavailability in some of the registers. Furthermore, confounding by indication is only an issue in  
16 hospitals that offer both bone scintigraphy and <sup>18</sup>F-NaF PET, which is highly uncommon in Denmark. Since  
17 sites only used one of the imaging modalities, physicians did not have to choose between the two, resulting in  
18 minimal selection bias. We attempted to control for confounding by using a propensity score-based inverse  
19 probability of treatment weighting, but we cannot rule out residual confounding due to misclassified or  
20 unmeasured prognostic factors. Multi-parametric magnetic resonance imaging (mpMRI) is also a factor worth  
21 considering in relation to targeted biopsies in the diagnostic work-up of prostate cancer. This method has been  
22 gradually implemented nationally in Denmark and prior to 2018 only very few sites had access to mpMRI for  
23 all patients, hence; we do not have data available yet. The introduction of mpMRI targeted biopsy is likely to  
24 affect the selection of patients for RP in the future

25 In the present study, we defined SREs as either external radiation therapy, pathological or osteoporotic  
26 fractures, spinal cord compression, surgery to the bone, or a bone metastases code. It can be speculated that  
27 patients treated at a site using <sup>18</sup>F-NaF PET would undergo <sup>18</sup>F-NaF PET rather than bone scintigraphy in case  
28 of biochemical recurrence, thereby increasing the detection of bone metastases during follow-up. However,  
29 the risk of SREs was primarily driven by a high percentage of radiotherapy of bone or fracture cases, which  
30 are not related to <sup>18</sup>F-NaF PET. Moreover, with the widespread introduction of prostate specific membrane  
31 antigen (PSMA) PET/CT in Denmark from 2015 and onwards, patients with biochemical recurrence would  
32 undergo PSMA PET/CT rather than <sup>18</sup>F-NaF PET/CT. Information regarding bone metastases was noted in  
33 only 6.3% of SREs across the groups.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Conclusions**

2 In conclusion, we found that the use of  $^{18}\text{F}$ -NaF PET at primary staging did not improve patient-relevant  
3 outcomes in terms of a reduction in SREs compared to that with bone scintigraphy.

For peer review only

## 1 **ACKNOWLEDGMENT SECTION**

### 2 **Author Contributions**

3 AWM, LJP and HDZ conceived the study and contributed to the literature search. AWM and CTP had access  
4 to the data and carried out the data management and analysis. AWM, CTP and MN designed the graphs. AWM,  
5 LJP, HDZ, CTP, MN and MTP aided in the interpretation of results. AWM prepared the first draft of the paper.  
6 All authors contributed to critical revision and approval of the final draft of the paper.

### 7 **Conflict of Interest Disclosure**

8 All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and  
9 declare: one author received grants from Bayer and Novo Nordisk for the submitted work; no financial  
10 relationships with any organizations that might have an interest in the submitted work in the previous three  
11 years; no other relationships or activities that could appear to have influenced the submitted work.

### 12 **Data availability statement**

13 Data is not available to other researchers due to Registry or institutional database of patients providing  
14 routinely collected data.

### 15 **Funding/Support**

16 Funding was received from the North Denmark Region's Fund for Health Sciences Research and from Knud  
17 and Edith Eriksens Mindefond. Award numberes are not applicable.

### 18 **Role of Funder/Sponsor**

19 The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or  
20 writing of the report.

21

1  
2  
3  
4 **1 REFERENCES**  
5

- 6  
7 2 1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and  
8 3 mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians* 2021 doi:  
9 4 10.3322/caac.21660 [published Online First: 2021/02/05]  
10 5 2. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. *Nat Rev Cancer* 2005;5(1):21-8.  
11 6 doi: 10.1038/nrc1528 [published Online First: 2005/01/05]  
12 7 3. Nørgaard M, Jensen A, Jacobsen JB, et al. Skeletal related events, bone metastasis and survival of  
13 8 prostate cancer: a population based cohort study in Denmark (1999 to 2007). *The Journal of*  
14 9 *urology* 2010;184(1):162-7. doi: 10.1016/j.juro.2010.03.034 [published Online First: 2010/05/21]  
15 10 4. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate  
16 11 Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.  
17 12 *European urology* 2020 doi: 10.1016/j.eururo.2020.09.042 [published Online First: 2020/11/12]  
18 13 5. NCCN. Clinical practice guidelines in oncology, Prostate Cancer version 2.2020, May 21 2020 [Available  
19 14 from: <http://www.nccn.com>  
20 15 6. Jambor I, Kuisma A, Ramadan S, et al. Prospective evaluation of planar bone scintigraphy, SPECT,  
21 16 SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone  
22 17 metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. *Acta oncologica*  
23 18 *(Stockholm, Sweden)* 2016;55(1):59-67. doi: 10.3109/0284186x.2015.1027411 [published Online  
24 19 First: 2015/04/03]  
25 20 7. Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk  
26 21 prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-  
27 22 fluoride PET, and 18F-fluoride PET/CT. *Journal of nuclear medicine : official publication, Society of*  
28 23 *Nuclear Medicine* 2006;47(2):287-97. [published Online First: 2006/02/04]  
29 24 8. Iagaru A, Mittra E, Dick DW, et al. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT,  
30 25 and (18)F FDG PET/CT for detection of skeletal metastases. *Molecular imaging and biology : MIB :*  
31 26 *the official publication of the Academy of Molecular Imaging* 2012;14(2):252-9. doi:  
32 27 10.1007/s11307-011-0486-2 [published Online First: 2011/04/12]  
33 28 9. Palmedo H, Marx C, Ebert A, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and  
34 29 effect on patient management in oncological patients. *European journal of nuclear medicine and*  
35 30 *molecular imaging* 2014;41(1):59-67. doi: 10.1007/s00259-013-2532-6 [published Online First:  
36 31 2013/08/27]  
37 32 10. Langsteger W, Balogova S, Huchet V, et al. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the  
38 33 detection of prostate cancer: prospective comparison of diagnostic performance determined by  
39 34 masked reading. *The quarterly journal of nuclear medicine and molecular imaging : official*  
40 35 *publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International*  
41 36 *Association of Radiopharmacology (IAR), [and] Section of the So* 2011;55(4):448-57. [published  
42 37 Online First: 2011/07/09]  
43 38 11. Mosavi F, Johansson S, Sandberg DT, et al. Whole-body diffusion-weighted MRI compared with (18)F-  
44 39 NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. *AJR*  
45 40 *American journal of roentgenology* 2012;199(5):1114-20. doi: 10.2214/ajr.11.8351 [published  
46 41 Online First: 2012/10/26]  
47 42 12. Gauthé M, Aveline C, Lecouvet F, et al. Impact of sodium (18)F-fluoride PET/CT, (18)F-fluorocholine  
48 43 PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate  
49 44 cancer suspicious for metastasis: a prospective multicentre study. *World journal of urology*  
50 45 2019;37(8):1587-95. doi: 10.1007/s00345-018-2547-5 [published Online First: 2018/11/02]  
51 46 13. Hillner BE, Hanna L, Makinen R, et al. Intended Versus Inferred Treatment After (18)F-Fluoride PET  
52 47 Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry.  
53 48 *Journal of nuclear medicine : official publication, Society of Nuclear Medicine* 2018;59(3):421-26.  
54 49 doi: 10.2967/jnumed.117.205047 [published Online First: 2017/12/02]  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 14. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. *Eur*  
5 2 *J Epidemiol* 2014;29(8):541-9. doi: 10.1007/s10654-014-9930-3 [published Online First:  
6 3 2014/06/27]
- 8 4 15. Gjerstorff ML. The Danish Cancer Registry. *Scand J Public Health* 2011;39(7 Suppl):42-5. doi:  
9 5 10.1177/1403494810393562 [published Online First: 2011/08/04]
- 10 6 16. Pedersen CB. The Danish Civil Registration System. *Scand J Public Health* 2011;39(7 Suppl):22-5. doi:  
11 7 10.1177/1403494810387965 [published Online First: 2011/08/04]
- 12 8 17. Schmidt M, Schmidt SA, Sandegaard JL, et al. The Danish National Patient Registry: a review of content,  
13 9 data quality, and research potential. *Clin Epidemiol* 2015;7:449-90. doi: 10.2147/clep.S91125  
14 10 [published Online First: 2015/11/26]
- 15 11 18. Arendt JFH, Hansen AT, Ladefoged SA, et al. Existing Data Sources in Clinical Epidemiology: Laboratory  
16 12 Information System Databases in Denmark. *Clin Epidemiol* 2020;12:469-75. doi:  
17 13 10.2147/clep.S245060 [published Online First: 2020/06/18]
- 19 14 19. Nguyen-Nielsen M, Høyer S, Friis S, et al. The Danish Prostate Cancer Database. *Clin Epidemiol*  
20 15 2016;8:649-53. doi: 10.2147/clep.S100256 [published Online First: 2016/11/16]
- 21 16 20. Erichsen R, Lash TL, Hamilton-Dutoit SJ, et al. Existing data sources for clinical epidemiology: the Danish  
22 17 National Pathology Registry and Data Bank. *Clin Epidemiol* 2010;2:51-6. doi: 10.2147/clep.s9908  
23 18 [published Online First: 2010/09/25]
- 24 19 21. Helweg-Larsen K. The Danish Register of Causes of Death. *Scand J Public Health* 2011;39(7 Suppl):26-9.  
25 20 doi: 10.1177/1403494811399958 [published Online First: 2011/08/04]
- 26 21 22. Gammelager HC, C.; Johansen, M.; Borre, M.; Schoonen, M.; Sørensen, H. Quality of urological cancer  
27 22 diagnoses in the Danish National Registry of Patients. *European Journal of Cancer Prevention*  
28 23 2012;21(6):545-51. doi: 10.1097/CEJ.0b013e328351c680
- 29 24 23. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in  
30 25 longitudinal studies: development and validation. *J Chronic Dis* 1987;40(5):373-83. doi:  
31 26 10.1016/0021-9681(87)90171-8 [published Online First: 1987/01/01]
- 32 27 24. Keogh JBaR. smcfcfs: Multiple Imputation of Covariates by Substantive Model Compatible Fully  
33 28 Conditional Specification. . <http://www.missingdata.org.uk>, <http://thestatsgeek.com>. , 2020:17.
- 34 29 25. Hicks RJ, Ware RE, Hofman MS. Not-so-random errors: randomized controlled trials are not the only  
35 30 evidence of the value of PET. *Journal of nuclear medicine : official publication, Society of Nuclear*  
36 31 *Medicine* 2012;53(11):1820-2; author reply 22-24. doi: 10.2967/jnumed.112.111351 [published  
37 32 Online First: 2012/10/05]
- 38 33 26. Lalumera E, Fanti S. Randomized Controlled Trials for Diagnostic Imaging: Conceptual and Practical  
39 34 Problems. *Topoi* 2019;38(2):395-400. doi: 10.1007/s11245-017-9535-z
- 40 35 27. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients  
41 36 with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a  
42 37 prospective, randomised, multicentre study. *Lancet* 2020;395(10231):1208-16. doi: 10.1016/s0140-  
43 38 6736(20)30314-7 [published Online First: 2020/03/27]
- 44 39 28. Akin-Akintayo OO, Jani AB, Odewole O, et al. Change in Salvage Radiotherapy Management Based on  
45 40 Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.  
46 41 *Clinical nuclear medicine* 2017;42(1):e22-e28. doi: 10.1097/rlu.0000000000001379 [published  
47 42 Online First: 2016/10/18]
- 48 43 29. Scheibler F, Zumbé P, Janssen I, et al. Randomized controlled trials on PET: a systematic review of  
49 44 topics, design, and quality. *Journal of nuclear medicine : official publication, Society of Nuclear*  
50 45 *Medicine* 2012;53(7):1016-25. doi: 10.2967/jnumed.111.101089 [published Online First:  
51 46 2012/06/09]
- 52 47 30. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. *N*  
53 48 *Engl J Med* 2009;361(1):32-9. doi: 10.1056/NEJMoa0900043 [published Online First: 2009/07/03]
- 54 49 31. Ruers TJ, Wiering B, van der Sijp JR, et al. Improved selection of patients for hepatic surgery of  
55 50 colorectal liver metastases with (18)F-FDG PET: a randomized study. *Journal of nuclear medicine :*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1           *official publication, Society of Nuclear Medicine* 2009;50(7):1036-41. doi:  
2           10.2967/jnumed.109.063040 [published Online First: 2009/06/16]  
3 32. Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research:  
4           from health care contacts to database records. *Clin Epidemiol* 2019;11:563-91. doi:  
5           10.2147/clep.S179083 [published Online First: 2019/08/03]  
6

For peer review only

## 1 **FIGURE LEGENDS**

2  
3  
4  
5  
6 2 (Figure 1-4 are attached as separate PDF files)

### 7 8 9 3 10 11 4 12 13 5 **Figure 1: Study profile**

14 6 Study cohort of 2,161 men undergoing presurgical imaging with bone scintigraphy and 807 men undergoing  $^{18}\text{F}$ -NaF  
15 7 PET. Patients with no or other imaging were combined since there were no differences between sites performing  $^{18}\text{F}$ -  
16 8 NaF PET or bone scintigraphy. Moreover, we experienced inconsistencies in the way CT and MR scans were coded in  
17 9 the registries, making it difficult to distinguish between imaging of the prostate and other sites.  
18  
19  
20  
21

### 22 11 **Figure 2: Unadjusted cumulative incidence of skeletal-related events (SREs)**

23 12 The unadjusted cumulative incidence with 95% confidence intervals of SREs in men after undergoing radical  
24 13 prostatectomy. Death was treated as a competing event. The red curve represents  $^{18}\text{F}$ -NaF PET, and the black curve  
25 14 represents bone scintigraphy.  
26  
27  
28

### 29 16 **Figure 3: Main analysis results**

30 17 Hazard ratios for SREs following radical prostatectomy among patients undergoing  $^{18}\text{F}$ -NaF PET before surgery versus  
31 18 patients undergoing bone scintigraphy.  
32  
33  
34

### 35 20 **Figure 4: Unadjusted cumulative incidence of death**

36 21 Unadjusted cumulative incidence of death with 95% confidence intervals for men with prostate cancer after undergoing  
37 22 radical prostatectomy, stratified by type of imaging modality. The red curve represents  $^{18}\text{F}$ -NaF PET, and the black  
38 23 curve represents bone scintigraphy.  
39  
40  
41

### 42 25 **Table 1: Baseline patient characteristics by imaging modality**

43 26 Characteristics on the day of surgery for men with high-risk prostate cancer from 2011 to 2018. Percentages may not  
44 27 add up to 100 due to rounding or missing data. \*Top 3 comorbidities. Abbreviations: IQR, interquartile range; PSA,  
45 28 prostate specific antigen; T-stage, tumour stage.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 TABLES

2

3 **Table 1. Baseline patient characteristics by imaging modality**

|  | Bone scintigraphy (n = 2,161) | <sup>18</sup> F-NaF PET (n = 807) | All (n = 2,968)   |
|--|-------------------------------|-----------------------------------|-------------------|
| Age (years, median (IQR))                              | 66.3 (61.7, 69.7)             | 67.9 (62.9, 71.2)                 | 66.7 (62.0, 70.1) |
| Year of surgery  |                               |                                   |                   |
| 2011-2013  | 852 (39.4)                    | 212 (26.3)                        | 1,064 (35.8)      |
| 2014-2015  | 602 (27.9)                    | 235 (29.1)                        | 837 (28.2)        |
| 2016-2018  | 707 (32.7)                    | 360 (44.6)                        | 1,067 (36.0)      |
| Imaging date before prostatectomy (days, median (IQR)) | 46 (32, 65)                   | 42 (28, 56)                       | 45 (30, 63)       |
| PSA (ng/mL)  |                               |                                   |                   |
| <10  | 955 (45.0)                    | 263 (33.1)                        | 1,218 (41.8)      |
| 10-20  | 642 (30.2)                    | 292 (36.8)                        | 934 (32.0)        |
| >20  | 526 (24.8)                    | 239 (30.1)                        | 765 (26.2)        |
| Gleason biopsy score                                   |                               |                                   |                   |
| <7   | 345 (16.2)                    | 70 (8.8)                          | 415 (14.2)        |
| 7  | 1225 (57.5)                   | 469 (58.6)                        | 1,694 (57.8)      |
| >7   | 560 (26.3)                    | 261 (32.6)                        | 821 (28.0)        |
| Clinical T-stage                                       |                               |                                   |                   |
| T1   | 259 (12.6)                    | 50 (7.5)                          | 309 (11.4)        |
| T2   | 1260 (61.5)                   | 241 (36.0)                        | 1,501 (55.2)      |
| T3-T4  | 529 (25.8)                    | 378 (56.5)                        | 907 (33.4)        |
| Comorbidity*   |                               |                                   |                   |
| Cardiovascular diseases                                | 118 (5.5)                     | 52 (6.4)                          | 170 (5.8)         |
| Other malignancies                                     | 102 (4.7)                     | 64 (7.9)                          | 166 (5.6)         |
| Diabetes   | 62 (2.9)                      | 48 (6.0)                          | 110 (3.7)         |
| Charlson comorbidity index                             |                               |                                   |                   |
| 1  | 267 (12.4)                    | 115 (14.3)                        | 382 (12.9)        |
| >1   | 203 (9.4)                     | 107 (13.3)                        | 310 (10.4)        |


4 Characteristics on the day of surgery for men with high-risk prostate cancer from 2011 to 2018. Percentages may not  
5 add up to 100 due to rounding or missing data. \*Top 3 comorbidities. Abbreviations: IQR, interquartile range; PSA,  
6 prostate specific antigen; T-stage, tumour stage.

7




# Figure 1: Study profile

Study cohort of 2,161 men undergoing presurgical imaging with bone scintigraphy and 807 men undergoing 18F-NaF PET.




### Figure 2. Unadjusted cumulative incidence of overall-related events (SREs)

The unadjusted cumulative incidence with 95% confidence intervals of SREs in men after undergoing radical prostatectomy. Death was treated as a competing event. The red curve represents 18F-NaF PET, and the black curve represents bone scintigraphy.




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

1 **Figure 3. Main analysis results**  
 2 Hazard ratios for SREs following radical prostatectomy among patients undergoing <sup>18</sup>F-NaF  
 3 PET before surgery versus patients undergoing bone scintigraphy.  
 4



### Figure 4. Unadjusted cumulative incidence of death

Unadjusted cumulative incidence of death with 95% confidence intervals for men with prostate cancer after undergoing radical prostatectomy, stratified by type of imaging modality. The red curve represents 18F-NaF PET, and the black curve represents bone scintigraphy.



## APPENDIX 1

**Table 1.** Registry data used in the analysis.


| Registry  | Code      |
|---|-----------|
| The Danish Cancer Registry                          |           |
| ICD-10 diagnosis and morphologic codes              |           |
| Prostate cancer                                     | DC61.9    |
| Tumor stage   | TNM       |
| The Danish National Registry of Patients            |           |
| Imaging modality                                    |           |
| Danish Health Care Classification System, sks-codes |           |
| Bone scintigraphy                                   | WKBxx     |
| <sup>18</sup> F-NaF PET                             | WDTPSFCXX |
| The Danish National Registry of Patients            |           |
| Primary prostate cancer treatment                   |           |
| NCSP codes  |           |
| Radical prostatectomy                               | KKECxx    |
| The Danish National Registry of Patients            |           |
| Skeletal-related events                             |           |
| NCSP codes  |           |
| Radiation to bone                                   | BWGxx     |
| Surgery to bone                                     | KNAGxx    |
| ICD-10 codes  |           |
| Bone metastases                                     | DC79.5    |
| Spinal cord compression                             | DG952     |
| Pathological fractures                              |           |
| Osteoporotic fractures                              |           |
| The Danish Register of Laboratory Results           |           |
| NPU codes   |           |
| PSA   | NPU0866   |
| The Danish National Pathology Registry              |           |
| SNOMED codes  |           |
| Gleason score                                       | ÆF0xx     |

NCSP: Nomesco Classification of Surgical Procedures; NPU: Nomenclature for Properties and Units; SNOMED: Systematized Nomenclature of Medicine


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60**Table 2.** Comorbidity codes from The Danish National Patient Registry used to calculate the Charlson Comorbidity Index. All codes are ICD-10 codes.

| Comorbidity                    | Code   |
|--------------------------------|--|
| Myocardial infarction          | DI21, DI22   |
| Heart failure                  | DI099, DI110, DI130, DI132, DI255, DI425, DI426, DI427, DI429, DI428A, DP290, DI43, DI50, DE105, DE115, DE125, DE135, DE145  |
| Peripheral vascular disease    | DI70, DI71, DI72, DI731, DI738, DI739, DI77, DI790, DI792, DK551, DK558, DK559, DZ958, DZ959   |
| Cerebrovascular disease        | DI60, DI61, DI62, DI63, DI64, DI65, DI66, DI67, DI68, DI69, DG45, DG46, DH340  |
| Dementia                       | DF00, DF01, DF02, DF03, DG30, DF051, DG311   |
| Chronic pulmonary disease      | DJ40, DJ41, DJ42, DJ43, DJ44, DJ45, DJ46, DJ47, DJ60, DJ61, DJ62, DJ63, DJ64, DJ65, DJ66, DJ67, DJ684, DI278, DI279, DJ84, DJ701, DJ703, DJ920, DJ953, DJ961, DJ982, DJ983   |
| Rheumatic disease              | DM05, DM06, DM08, DM09, DM30, DM31, DM32, DM33, DM34, DM35, DM35, DM36, D86  |
| Peptic ulcer disease           | DK25, DK26, DK27, DK28, DK221  |
| Mild liver disease             | DB18, DK700, DK701, DK702, DK709, DK703, DK713, DK714, DK715, DK717, DK73, DK74, DK760, DK762, DK763, DK764, DK769, DZ944  |
| Severe liver disease           | DB150, DB160, DB162, DB190, DI850, DI859, DI864, DI982, DK704, DK711, DK721, DK729, DK765, DK766, DK767  |
| Diabetes without complications | DE100, DE101, DE108, DE109, DE110, DE111, DE119, DE120, DE121, DE129, DE130, DE131, DE139, DE140, DE141, DE149   |
| Diabetes with complications    | DE102, DE103, DE104, DE105, DE106, DE107, DE112, DE113, DE114, DE115, DE116, DE117, DE118, DE122, DE123, DE124, DE125, DE126, DE127, DE128, DE132, DE133, DE134, DE135, DE136, DE137, DE138, DE142, DE143, DE144, DE145, DE146, DE147, DE148 |
| Hemiplegia paraplegia          | DG830, DG831, DG832, DG833, DG834, DG81, DG82, DG041, DG114, DG801, DG802, DG839   |
| Renal disease                  | DN032, DN033, DN034, DN035, DN036, DN037, DN052, DN053, DN054, DN055, DN056, DN057, DZ490, DZ491, DZ492, DN18, DN19, DI120, DI131, DI132, DN250, DZ940, DZ992, DN26  |
| Any malignancy                 | DC0, DC1, DC2, DC3, DC40, DC41, DC42, DC43, DC44, DC45, DC46, DC47, DC48, DC49, DC5, DC6, DC70, DC71, DC72, DC73, DC74, DC75, DC76, DC86, DC97   |
| Metastatic solidtumor          | DC77, DC78, DC79, DC80   |
| AIDS/HIV                       | DB20, DB21, DB22, DB23, DB24   |
| Leukemia                       | DC91, DC92, DC93, DC94, DC95   |
| Lymphoma                       | DC81, DC82, DC83, DC84, DC85, DC88, DC90, DC96   |

**Figure 1.** Unadjusted cumulative incidence with 95% confidence interval of skeletal-related events (SRE) in men after undergoing radical prostatectomy, restricted to men from the Capitol region of Denmark. Death was treated as a competing event. Red curve represents  $^{18}\text{F}$ -NaF PET, black curve bone scintigraphy.



**Figure 2.** Hazard ratios for skeletal-related events following radical prostatectomy among patients receiving a  $^{18}\text{F}$ -NaF PET before surgery compared with patients receiving a bone scintigraphy. Restricted to the Capitol region of Denmark.





**Table 3.** Demographics for the Capitol region of Denmark. Baseline characteristics on the day of surgery for men with high-risk prostate cancer from 2011-2018\* Stratified by pre-surgery imaging.

|                            | <b>Bone scintigraphy (n=690)</b> | <b><sup>18</sup>F-NaF PET (n=740)</b> | <b>All (n=1,430)</b> |
|----------------------------|----------------------------------|---------------------------------------|----------------------|
| Age (year, median (IQR))   | 66.2 (60.8, 69.3)                | 67.9 (62.9, 71.1)                     | 66.9 (61.9, 70.1)    |
| Year of surgery            |                                  |                                       |                      |
| 2011-2013                  | 331 (48.0)                       | 212 (28.6)                            | 543 (38.0)           |
| 2014-2015                  | 185 (26.8)                       | 231 (31.2)                            | 416 (29.1)           |
| 2016-2018                  | 174 (25.2)                       | 297 (40.1)                            | 471 (32.9)           |
| PSA (ng/mL)                |                                  |                                       |                      |
| <10                        | 300 (44.1)                       | 250 (34.4)                            | 550 (39.1)           |
| 10-20                      | 229 (33.6)                       | 271 (37.3)                            | 500 (35.5)           |
| >20                        | 152 (22.3)                       | 206 (28.3)                            | 358 (25.4)           |
| Gleason score              |                                  |                                       |                      |
| <7                         | 81 (12.0)                        | 61 (8.3)                              | 142 (10.1)           |
| 7                          | 401 (59.6)                       | 432 (58.9)                            | 833 (59.2)           |
| >7                         | 191 (28.4)                       | 240 (32.7)                            | 431 (30.7)           |
| Clinical T-stage           |                                  |                                       |                      |
| T1                         | 58 (9.0)                         | 39 (6.3)                              | 97 (7.7)             |
| T2                         | 435 (67.3)                       | 220 (35.8)                            | 655 (51.9)           |
| T3-T4                      | 153 (23.7)                       | 356 (57.9)                            | 509 (40.4)           |
| Comorbidity                |                                  |                                       |                      |
| Cardiovascular diseases    | 35 (5.1)                         | 46 (6.2)                              | 81 (5.7)             |
| Other malignancies         | 29 (4.2)                         | 59 (8.0)                              | 88 (6.2)             |
| Diabetes                   | 21 (3.0)                         | 44 (6.0)                              | 65 (4.6)             |
| Charlson comorbidity index |                                  |                                       |                      |
| 1                          | 84 (12.2)                        | 103 (13.9)                            | 187 (13.1)           |
| >1                         | 59 (8.6)                         | 97 (13.1)                             | 156 (10.9)           |

\*Percentages may not sum to 100 due to rounding or missing data

IQR: Interquartile range; PSA: Prostate specific antigen; T-stage: Tumor stage.

## STROBE (Strengthening The Reporting of OBServational Studies in Epidemiology) Checklist

A checklist of items that should be included in reports of observational studies. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

| Section and Item     | Item No. | Recommendation   | Reported on Page No. |
|----------------------|----------|--|----------------------|
| Title and Abstract   | 1        | (a) Indicate the study's design with a commonly used term in the title or the abstract   |                      |
|                      |          | (b) Provide in the abstract an informative and balanced summary of what was done and what was found  |                      |
| <b>Introduction</b>  |          |  |                      |
| Background/Rationale | 2        | Explain the scientific background and rationale for the investigation being reported   |                      |
| Objectives           | 3        | State specific objectives, including any prespecified hypotheses   |                      |
| <b>Methods</b>       |          |  |                      |
| Study Design         | 4        | Present key elements of study design early in the paper  |                      |
| Setting              | 5        | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection  |                      |
| Participants         | 6        | (a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up<br><br><i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls<br><br><i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants |                      |
|                      |          | (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed<br><br><i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case   |                      |
| Variables            | 7        | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable   |                      |

| Section and Item             | Item No. | Recommendation  | Reported on Page No. |
|------------------------------|----------|---|----------------------|
| Data Sources/<br>Measurement | 8*       | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group  |                      |
| Bias                         | 9        | Describe any efforts to address potential sources of bias   |                      |
| Study Size                   | 10       | Explain how the study size was arrived at   |                      |
| Quantitative Variables       | 11       | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why  |                      |
| Statistical Methods          | 12       | (a) Describe all statistical methods, including those used to control for confounding   |                      |
|                              |          | (b) Describe any methods used to examine subgroups and interactions   |                      |
|                              |          | (c) Explain how missing data were addressed   |                      |
|                              |          | (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed<br><i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed<br><i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy |                      |
|                              |          | (e) Describe any sensitivity analyses   |                      |
| <b>Results</b>               |          |   |                      |
| Participants                 | 13*      | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed   |                      |
|                              |          | (b) Give reasons for non-participation at each stage  |                      |
|                              |          | (c) Consider use of a flow diagram  |                      |
| Descriptive Data             | 14*      | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders  |                      |
|                              |          | (b) Indicate number of participants with missing data for each variable of interest   |                      |
|                              |          | (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)  |                      |
| Outcome Data                 | 15*      | <i>Cohort study</i> —Report numbers of outcome events or summary measures over time   |                      |
|                              |          | <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure  |                      |
|                              |          | <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures  |                      |

| Section and Item         | Item No. | Recommendation   | Reported on Page No. |
|--------------------------|----------|--|----------------------|
| Main Results             | 16       | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included |                      |
|                          |          | (b) Report category boundaries when continuous variables were categorized  |                      |
|                          |          | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   |                      |
| Other Analyses           | 17       | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses   |                      |
| <b>Discussion</b>        |          |  |                      |
| Key Results              | 18       | Summarise key results with reference to study objectives   |                      |
| Limitations              | 19       | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias   |                      |
| Interpretation           | 20       | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                                   |                      |
| Generalisability         | 21       | Discuss the generalisability (external validity) of the study results  |                      |
| <b>Other Information</b> |          |  |                      |
| Funding                  | 22       | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based  |                      |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.**